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      INTRODUCTION 
 
                        In the past few decades, extensive attention has been focused on the growth of 
new drug delivery system. The significant of NDDS, it should be deliver the drug at a rate 
directed by the needs of the body, over period of time. A number of NDDS have emerged 
encompassing various route of administration to achieve controlled and target drug delivery.  
 
                  Recently different types of carrier system s and technologies have been briefly 
studied with the aim of controlling the drug release and improving the worth and selectivity of 
formulation. And to minimize drug degradation and loss, to prevent the harmful side effects and 
increased the bioavailability and the fraction of the drug accumulate in the required zone, various 
drug delivery and drug targeting systems are developed. The targeting is the capability to direct 
the drug two major mechanisms can be notable for desire sites for drug release (1) passive,        
(2) active targeting controlled release. 
 
 
Drug delivery carrier:  
 
                         Colloidal drug carrier systems as micellar solutions, vesicle and liquid crystal 
dispersion, as well as nanoparticle dispersion consist of small particles of 10-400 nm in diameter 
is effective drug delivery system. When developing these are formulations to generate systems 
with optimized drug loading and release properties, long shelf life and low toxicity. The 
incorporated drug participates in the microstructure of the system and may persuade it due to 
molecular interactions, especially if the drug posses amphiphillic and or mesogenic properties. 
Drug delivery system using colloidal particulate carriers such as liposomes, niosomes and 
proniosomes have distinct advantages over conventional dosage forms. These liposomes, 
niosomes, proniosomes are used to improve the therapeutic index of both existing and new drug 
molecules by encapsulating an active medicament inside vesicular structure in one such 
system.(Dwarakandha reddy.P,et.al.,2010) 
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Introduction of vesicular system 
   Vesicular system is one of the development novel drug delivery system. The 
development of vesicle as a carrier system have been become the vesicle choice in drug delivery 
and lipid vesicle were found to be a value in immunology, membrane biology, and diagnostic 
technique and most recent in genetic engineering. Vesicular system providing an efficient 
method for delivery to the site of infection, and reduce toxicity of drug and no adverse effect. It 
reduces the cost of therapy by improving bioavailability of drug especially for poorly soluble 
drug. They can incorporate both liphophilic and hydrophilic drugs. The different types vesicular 
system such as liposomes, proniosomes, noisome, transferosome and pharmacosomes. 
Vesicular system- carrier for drug delivery 
   The vesicular systems are highly ordered assemblies of one or several concentric 
lipid bilayers formed, when certain amphiphilic building blocks. Drug carrier can be engineered 
to slowly degrade, react to stimuli and be site-specific. To control degradation of drug and loss, 
prevention of harmful side effects and increases the bioavailability of the drug at the disease site. 
Encapsulation of a drug in vesicular structures can be predict to prolong the existence of the drug 
in systemic circulation, and perhaps, reduces the toxicity if selective update can be 
achieved.(kavitha,et,al.,2010). 
Advantages of vesicular system 
 Prolong the existences of the drug in systemic and perhaps, reduces the toxicity if 
selective uptake can be achieved due to the delivery of drug directly to the site of 
infection. 
 Improves the bioavailability especially in the case of poorly soluble drugs. 
 Both hydrophilic and liphophilic drugs can be incorporated. 
 Delays elimination of rapidly metabolizable drug and thus function as sustained release 
system. 
 Liposomes 
    The liposomes have join as most practically useful carriers for in vivo drug 
delivery as majority of formulations has concentrated on the of phospholipids vesicles or 
liposomes as potential drug carrier system. Liposomes or lipid base vesicles are microscopic 
vesicles that are formed as result self assembly of phospholipids in an aqueous media resulting 
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closed the belayed structures. This system is a closed bilayered structures is a spontaneous 
process and usually needs some input energy in the form of physical agitation, sonication, heat 
etc. The lipid bilayered membrane enclosed aqueous core, both water and lipid soluble drugs can 
be successfully entrapped into the liposomes. The lipid soluble drug or liphophilic drug get 
entrapped into bilayered membrane whereas water soluble or liphophilic drugs gets entrapped in 
to central of aqueous core of the vesicles. Liposomes are potential carrier for controlled drug 
release of tumors therapeutic agents of antibiotic, for gene and antisense through nucleic acid, 
sequence delivery, immunization though antigen and anti-Parkinson’s.(Ravi kumar,et,al.,2011) 
Advantages 
 Liposomes supply both a lipophilic environment and aqueous milieu interne” in one 
system and are therefore suitable for delivery of hydrophobic, amphipathic and 
hydrophilic drugs and agents. 
 Liposomes could encapsulate not only small molecules but also macromolecules like 
superoxide dissimulates hemoglobin, erythropoietin, interleukin-2 and interferon-g. 
 Liposomes reduced toxicity and increased stability of entrapped drug via encapsulation. 
 Liposomes help to reduced exposure of sensitive tissues to toxic drugs. 
Disadvantages 
 Less stability (chemical and physical instability) 
 High production cost 
 Leakage and fusion of encapsulated drug 
 Sometimes phospholipid undergoes oxidation and hydration 
Niosomes 
   Niosomes are non-ionic surfactant vesicles that entrap a solute in a manner 
analogous to liposomes. They are osmotically active, and a stability of the entrapped drugs. 
Handling and storage of surfactants required no special condition. Niosomes having 
infrastructure consisting of hydrophilic and hydrophobic moieties together, and as a result, can 
accommodate drug molecules with a range of solubility’s.(Akhilesh.D el,al.,2011) Niosomes as 
drug carrier have shown advantages such as being cheap and chemically stable, they are 
associated with problem related to physical stability such as fusion, aggregation, sedimentation 
and leakage on storage. The size of niosomes is microscopic and lies in nanometric scale. The 
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particle size ranges from 10nm-100nm.( Sudhamani.T.et,al.,2010, Ravi kumar,et,al.,2011, Narayan 
DuttShukla,et,al.,2011) 
 
 
Figure: 1 Structure of Niosomes 
Disadvantage of Niosomes 
 Physical instability 
 Aggregation 
 Fusion 
 Leaking of entrapped drug 
 Hydrolysis of encapsulated drugs which limiting the self life of the dispersion 
PRONIOSOMES 
   Proniosomes is dry formulation using suitable carrier coated with non-ionic 
surfactant and can be converted into niosomes immediately before use by hydration. The 
proniosomes are minimize the problem of niosomes physical stability such as aggregation, fusion  
and leaking and provide additional convenience in transportation, distribution, storage and 
dosing.(RishuKakar,et,al.,2010) 
Types of proniosomes 
Dry granular proniosomes 
   According to the type of carrier and method of preparation of dry granular 
proniosomes are  
I. Sorbitol based proniosomes 
II. Maltodextrin based proniosomes 
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   Sorbitol based proniosomes is a dry formulation that involves sorbitol as a carrier, 
which further coated with non ionic surfactant and is used as a niosomes within minutes by 
addition of hot water following the agitation. These are normally made by spraying surfactant 
mixture prepared by organic solvent on to the sorbitol powder and then evaporating the solvent. 
The residual sorbitol decrease the entrapment efficiency to less than one half of that observed 
without sorbitol. The difficulties lie in testing of sorbitol particles because sorbitol is soluble in 
chloroform and organic solvents. It is prepared by sloe slurry method.(Walve J.R,et,al.,2011) 
   Maltodetrin based proniosomes prepared by fast slurry method. Time required to 
produce proniosome by slurry method is independent of the ratio of surfactant solution to carry 
out. Proniosomes of high surface to carriers ratio can be prepared. The preparation has potential 
of application in delivering of hydrophobic and amphiphilic drugs. 
Liquid crystalline proniosomes 
   When the surfactant molecule are kept in contact with water, there are three ways 
low  which liphophilic chains of surfactants can be transformed into a disordered, liquid state 
called lyotropic liquid crystalline state. This method avoids the use of pharmaceutically 
unacceptable solvents and it is easy to scale up. This system may directly be formulated into 
transdermal patch, up to hydration with water from skin it may be converted into niosomes. As 
the formulation is in direct contact with skin, it itself act as permeation enhancer.(Walve 
J.R,et,al.,2011) 
Mechanism of Action 
   On the transdermal/ topical application of  vesicle have rendered conflicting 
results. The four  types of mechanism used in vesicle-skin interactions observed in human skin 
which  induced various effects on dermal or transdermal delivery system. 
   Proniosomal gel vesicles are composed both nonionic surfactant and 
phospholipids both can act as penetration enhancer and useful increase penetration power of 
many drugs. The proniosomal formulations can increase amount of drug permeated through the 
stratum corneum. The hypothetical mechanism of skin permeation related to a possible 
reorganization of the proniosomal membrane at the level of stratum corneum. The improved drug 
passage through the outer skin layer seems to be medicated by the high flexibility of the bilayer 
structure.  
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   There is a direct contact of proniosomal gel with skin. Proniosomal gels are 
composed to the non ionic surfactant, these are mainly interact with skin. The hydrogen bonding 
will strengthen and stabilize the lipid bilayer and as a result will pass on the barrier property of 
stratum corneum. 
 Adsorption and fusion of proniosomal gel on the surface of skin leading to a high 
thermodynamic activity gradient of drug at the interface, which is the driving forces 
for permeation of lipophillic drug. 
 The penetration enhancers effect of vesicles to reduce stratum corneum barrier 
property. 
 Interactions are the skin formulation interface involve adsorption and fusion of vesicle 
of proniosomes on the stratum corneum structure, resulting in a new structure 
formation. 
 Vesicle skin interactions are found in the deeper layers of stratum corneum involve 
bilayer alter structure.(Ashwini singh rawat et al.,2011,Nidhipanday et al.,2011, 
Geetha agarrwal et al., 2010,KiranYadav et,al.,2010) 
 
   In addition of the several other mechanism which could explain the ability of 
vesicle to modulate drug transfer across skin, including: 
 Nature of drug  
 The vesicles act as penetration enhancers to reduce the barrier properties of the skin 
 Size and composition of vesicles 
 Biophysical factors  
Materials used in proniosomal gel 
   Proniosomal gel is generally consisting of non-ionic surfactant, lecithin, alcohol, 
aqueous phase and miscellaneous. 
Surfactant 
    The selection of surfactant should be done on the basis of HLB value. As 
hydrophilic lipophilic Balance is a good indicator of the vesicle forming ability of any surfactant, 
HLB number in between 4 and 8 was found to be compatible with vesicle formation. The HLB 
values are responsible for degree of entrapment efficiency. Transition temperature of surfactant 
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also affects the entrapment of drug in vesicles. Span with highest phase transition temperature 
provide the highest entrapment efficiency for the drug.(Walve J.R,et,al.,2011,Kiranyadev,et,al.,2010) 
Phosphatidyl choline 
   Phosphatidyl choline is a major component of lecithin. Depending upon the 
source it is named into egg lecithin and soya lecithin. Lecithin used in a Proniosomal gel as 
permeation enhancers. Adding of lecithin in Proniosomes is produce the percentage of 
entrapment should be increased and to produce vesicle in smaller size due to increase the 
hydrophobicity which result in reduction of vesicle size. There is probably formation of more 
compact and well organized bi-layers which prevents the leakage of drug. 
Cholesterol  
   Cholesterol is important for the vesicle formation. It is response for an entrapment 
of drug in vesicles. There are reports that entrapment efficiency increase with increase the 
cholesterol content and by usage of span 60 which higher transition temperature. It was also 
observed that very high cholesterol content had a lowering effect on drug entrapment to the 
vesicle. This could be due to the fact that cholesterol beyond a certain level starts disrupting the 
regular bi-layered structure leading to loss of drug entrapment. 
Solvent  
   Alcohol used in Proniosomal preparation has a great effect on vesicle size and 
drug permeation rate. Vesicle formed from different alcohols are of different size and they 
follow order Ethanol> Propanol>Butanol> isopropyl alcohol. Highest size of vesicle in case of 
ethanol is due to its greater solubility in water and smallest in size of isopropyl alcohol, may be 
due to branched chain present in it. 
Aqueous phase 
   Phosphate buffer p
H
 7.4, 0.1% glycerol, hot water is used as aqueous phase in 
preparation of Proniosomal gel.(Kiranyadev,et,al.,2010,Walve J.R,et,al.,2011) 
Preparation of Proniosomes 
   The Proniosomes are prepared by different methods such as  
 Slurry method. 
 Coacervation phase separation method 
 Slow spray-coating method 
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  Slurry method 
   Maltodextrin powder 10 gm as carrier is added to a 250 ml round bottom flask 
and the entire volume of surfactant solution was added directly to the flask to form slurry. If the 
surfactant solution volume is less, then additional amount of organic solvent can be added to get 
slurry. The flask is attached to the rotary evaporator and vacuum is applied until the powder 
appeared to be dry and free flowing. The flask was removed from the evaporator and kept under 
vacuum overnight. Proniosomes powder was stored in sealed containers at 4
0
C. The time 
required to produce Proniosomes is independent of the ratio of surfactant solution to carrier 
material and appear to be scalable. (Thejaswi.C,et,al.,2011,Raja K,et,al.,2011) 
Advantages 
 Maltodextrin is a polysaccharide easily soluble in water and it is used as carrier material 
in formulation, it is easily coat the maltodextrin particles by simply adding surfactant in 
organic solvent to dry maltodextrin. 
 Due to uniform coating on carrier it protects the active ingredients and surfactant from 
hydrolysis and oxidation etc. 
 The higher surface area results in a thinner surfactant coating, which makes the 
rehydration process more efficient.  
Coacervation phase separation method 
   In this method, the weighed amounts of surfactant, lipid and drug are taken in a 
clean and dry wide mouthed glass vial of 5 ml capacity and alcohol is added to it. After warming, 
all the ingredients are mixed well with a glass rod, the open end of the glass bottle is covered 
with lid to prevent the loss of solvent from it and warmed over water bath at 60-70
0
c  for about 5 
min until the surfactant mixture is dissolved completely. 
(IbrahimA.Alsara,et,al.,2005,IntakhabAlam,et,al.,2010Chandra.A,el,al.,2008,) Then the aqueous phase 
is added and warmed on a water bath till a clear solution formed which is then converted into 
Proniosomal gel on cooling.(Hanan.M.Ei-laithy,et,al.,2011,NandKishore,et,al.,2010) 
Advantages 
 Method is simple and without time consumable so it does required any specialized 
equipment. 
 Specially adopted for gel preparation. 
 Small quantities or small dose formulation can be prepared on lab scale. 
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 It is used to reduce the side effects of drug and increased therapeutic effectiveness. 
Slow spray-coating method 
   In this method, the Proniosomes are prepared by spraying surfactant in organic 
solvent onto sorbitol powder and then evaporating the solvent. The sorbitol carrier is soluble in 
the organic solvent, it is necessary to repeat the process until the desired surfactant loading has 
been achieved. This method was reported to be tedious since the sorbitol carrier for formulating 
Proniosomes is soluble in the solvent used to deposit the surfactant. Sorbitol is also found to 
interfere with the encapsulation of certain drugs.(SankarV,et,al.,2010) 
Advantages 
 Simple method and suitable for hydrophobic drug without concerns of instability or 
susceptibility of active pharmaceutical ingredient to hydrolysis. 
Advantages of Proniosome over the Liposome and Niosome 
   The disadvantages of liposome and noisome are overcome by Proniosome. 
 Liposome and Niosome have a problem of degradation by hydrolysis or oxidation. 
 Liposome and Niosome are required special storage and handling. 
 Sedimentation, aggregation or fusion on storage is usually seen in liposomes and 
Niosome. 
 Purity of natural phospholipids is also varied in Liposome. 
 Difficult in transportation, distribution, storage. 
 Difficult in uniform of dose and scale up. 
   The design of the transdermal drug delivery system should be primarily aimed at 
achieved more predictable and increased bioavailability of drugs. Targeting the drug to the desire 
site of action would not only improve therapeutic efficacy but also enable a reduction of amount 
of the drug which must be administrated to achieve a therapeutic response, thus minimized 
unwanted toxic effects.( Sudhamani.T.et,al.,2010) 
INTRODUCTION OF TRANSDERMAL DRUG DELIVERY SYSTEM: 
   The transdermal drug delivery is one most important of the novel drug delivery 
system. The transdermal drug delivery is one of the most effective methods of applications. 
Transdermal patches are flexible pharmaceutical preparations of varying sizes, containing one or 
more active substances. They are intended to be applied to the unbroken skin in order to deliver 
the active substance(s) to the systemic circulation after passing through the skin barrier. In this 
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drug delivery system, across the skin to have an effect on the adjacent to the site of application or 
to have an effective distribution of the systemic circulation. 
    TDDS has been an increased interest in the drug administration via the skin for 
both local therapeutic effects on diseased skin as well as for systemic delivery of drug. 
                        TDDS has provide many advantages over conventional method are frequency 
excessive toxic and sometimes ineffective. The conventional drugs are in the form of tablets, 
capsules, injectables and ointment of in the body as pulses that usually produce large fluctuations 
of drug concentration in the blood stream and tissues.  
                       Transdermal delivery system has provide an improved approach to the 
administration of drug by maintaining therapeutic constant concentration of the drug in the blood 
for desired period of time, high bioavailability and the fact that is non-invasive. 
Transdermal delivery enables avoidance of gastrointestinal absorption and hepatic first pass 
metabolism. It produces not only the controlled constant administration of drug, but also 
continues input of drugs with short biological half life and eliminates the pulses into systemic 
circulation which often cause undesirable side effects.  
ADVANTAGES OF TDDS 
The advantages of transdermal drug delivery system follow as (Eseldinkeleb,et.al. 
2011,Tyagi.R.K,et,al., 2011) 
 To avoid first pass metabolism, salivary metabolism and Intestinal metabolism. 
 It is very useful for self medications to patients. 
 In case of any emergency or reactions produced means removing the patch at any point of 
time during therapy can instantly stop drug input. 
 Drugs showing gastrointestinal irritation and absorption can be suitably administered 
through the skin. 
 It is convenient to non invasive route. 
 Avoid the risk and Incovenience of IV therapy. 
 Byepass Veriation in absorbance permits continues drug administraton. 
 Reduce the chances of over dose or under dosing through prolonged , Preprogrammed 
delivery of drug at the required therapeutic rate. 
 It provides reduce the dose frequency, so there is better patient compliance. 
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 Therapeutic failures associated with irregularities in the dosing with conventional 
therapies can be avoided. 
 The adverse effects are minimized due to a steady and optimum blood concentration time 
profile. 
 The release rate more prolong than compared to oral sustained drug delivery systems. 
 The daily doses require is lower than that with conventional therapies. 
 The drug release is such that there is a predictable and extended duration of activity. 
 It can be used for chronic conditions where drug therapy is desired for a long period of 
time. e.g. Hypertension, Angina and Diabetics etc. 
 Transdermal therapy is not feasible for ionic drugs. 
 It cannot deliver drug in pulsate fashion. 
FACTORS AFFECTING TDDS   
1. Physicochemical properties of permeation  
   1.1 Partition coefficient 
    For molecules with intermediate partition coefficient and for highly lipophilic 
molecules, the intercellular route will be almost the pathway used to traverse the stratum 
corneum. These molecules are ability of partition out of the stratum corneum into the aqueous 
viable epidermal tissues. For more hydrophilic molecules, the transcelluar probably 
predominates. A water partition coefficient of 1 or garter is generally required for optimal 
transdermal permeability. It may be altered by chemical modification without affecting the 
pharmacological activity of the drug. 
   1.2 Molecular size 
     In this factor in determining the flux of a material through human skin is the size 
of the molecule. Molecular size is inversely relationship existed between transdermal flux and 
molecular weight of the molecules. In transdermal delivery the drug used within narrow range of 
molecular weight.(100-500). 
1.3 Solubility/Melting point 
   The most organic materials with high melting points have relatively low aqueous 
solubility at normal temperature and pressure. The liphophilic molecules tend to permeate 
though the skin faster than more hydrophilic molecules. Liphophilicity is a desired property of 
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transdermal candidates, it is also necessary for the molecule to exhibit some aqueous solubility 
since topical medicaments are generally applied from an aqueous formulation.                   
1.4 Ionization   
              A unionized form drug can more permeate though the lipid barrier than compare 
to ionized drugs. 
 1.5 Other factors 
   Interactions between drug substance and their tissue can vary from hydrogen 
bonding to weak Vander Waals forces, and the effect of drug binding on flux across the tissue 
will vary depending on the permeate. Depending on the type of formulation selected, other may 
be important in a transdermal delivery system. (Vinod K,et,al.,2010) 
2. Physiological factors 
2.1 Skin barrier property in the neonate and young infant 
    The skin of new born is known to relative susceptible to irritants, other variables 
related to stratum corneum function such as p
H
 and stratum corneoum hydration may enhance the 
irritant potential to newborn skin. Skin surface pH values in new born are significantly higher in 
all body sites than those in adult skin. There are also changes in the metabolic capacity are not 
observed until 2 months or even 6-12 months of age which may additionally account for the 
sensitivity of baby skin to irritants. The skin surface of the newborn is slightly hydrophobic and 
relatively dry and rough when compare to older infants. 
2.2Skin barrier properties in aged skin 
   The aged has no of physiological changes than compare to other skins. The 
corneocytes area shown to increase in surface area which may have implications for stratum 
corneum function due to resulting decrease the volume of inter neomeoctye space per unit 
volume of stratum corneum. The moisture content of human skin is decrease with age. There is 
flattening of the dermo epidermal junction. The area available for diffusion into the dermis is 
diminished. 
2.3 Race 
    Radical differences between black and white skins have been shown in some 
anatomical and physiology functions of the skin. In black skin, increased intracellular cohesion, 
higher lipid content and higher electrical skin resistance levels compared to whites have been 
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demonstrated. Black skin suggesting the stratum corneum modulates the different radical 
response to irritant. 
2.4 Body    
   The relative permeability of different skin sites is not simply a function of stratum 
corneum thickness as a different premeants exhibit varied rank orders through different skin 
sites. It is apparent that genital tissue usually provides the most permeable site for transdermal 
drug delivery. The skin of the head and neck is also relatively permeable compared to other sites 
of the body such as the arm and legs. 
3. Physiological factors 
    Numerous disorders result in an eruption of the skin surface. In this case, the 
barrier properties of the stratum corneum are compromised, allowing the passage of drug into 
and through the skin. The skin disease associated with reduced barrier skin function with trans 
epidermal water loss up to twenty times higher in active disease. The reduced barrier function, 
which correlated with signs of scaling, enables increased percutaneous absorption of topically 
applied compounds. The plagues are largely devoid of intercellular lipid, reducing the 
convoluted lipid pathway to the dermo epidermal junction, thus enhancing permeation.(Vinod 
K,et,al.,2010) 
TYPES OF TRANSDERMAL PATCHES: 
   The different type of transdermal systems were developed and fabricated. The 
types TDDS such as 
 Matrix type 
 Reservoir type 
 Membrane matrix type 
 Micro reservoir type 
 Drug in adhesive type 
Matrix type 
   Drug reservoir is prepared by dissolving the drug and polymer in a common 
solvent. The insoluble drug should be homogenously dispersed in hydrophilic or lipophillic 
polymer. The required quantity of plasticizer and permeation enhancer is then added and mixed 
properly. The medicated polymer formed is then molded into rings with defined surface area and 
controlled thickness over the mercury on horizontal surface followed by solvent evaporation at 
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an elevated temperature. The film formed is then separated from the rings, which is then 
mounted onto an occlusive base plate in a compartment fabricated from a drug impermeable 
backing. Most of the matrix patches are prepared by solvent evaporation 
method.(GeetaArrarwalet.al., 2009) Commonly used of matrix are cross linked polyethylene 
glycol, eudregit, ethyl cellulose, polyvinyl pyrrolidone and hydroxyl propyl methyl cellulose. 
 
  
                                     Figure:2 Design of matrix type transdermal patches 
 
 
 
Reservoir type transdermal patches 
  Drug reservoir prepared by homogeneously dispersing drug particle in a rate 
controlling polymer matrix fabricated from either a lipophillic or a hydrophobic polymer. The 
drug dispersion in the polymer matrix is accomplished by either (1) blending a therapeutic dose 
of finely ground drug particles with a liquid polymer or a highly viscous base polymer, followed 
by cross linking of the polymer chains, or (2) mixing drug solids with a rubbery polymer at 
elevated temperature. The resultant drug-polymer dispersion is then molded or extruded to form 
drug delivery device of various shape and sizes designed for specific applications.  It can also 
fabricated by dissolving the drug and polymer in a common solvent, followed by solvent 
evaporation at an elevated temperature.  
   The drug reservoir is made up of homogenous dispersion of drug particle 
suspended in an unleachable viscous liquid medium to form a paste like suspension or gel or a 
clear solution of drug in an evaporating solvent. The drug reservoir is made by sandwiched 
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between rate controlling membrane and backing laminate layer.(Debjitbhowmiket,al.,2010) Rate 
controlling membrane materials are such as EVA, ethyl cellulose, silicon rubber, and 
polyurethanes. 
  
                      Figure: 3 Design of reservoir type transdermal patches 
   The rate controlling membrane may be prepared by solvent evaporating method. 
The solvent evaporation by polymer is dissolved in solvent with or without plasticizer. The 
solution poured on the horizontal surface and left for evaporation of solvent in order to obtain a 
thin film. The main advantage of reservoir type patches is that this patch design can provide at 
zero order release pattern to achieve a constant serum drug level. 
 
Membrane matrix hybrid type patches 
   This is the modification of reservoir type transdermal patch. The liquid 
formulation of the drug reservoir is replaced with a solid polymer matrix which is sandwiched 
between rate controlling membrane and backing laminate.(GeetaArrarwalet.al., 2009) 
Micro reservoir type transdermal patches 
   The drug reservoir is formed by suspending the drug in an aqueous solution of 
water miscible drug solubilizer e.g. polyethylene glycol. The drug suspension is homogenously 
dispersed by a high shear mechanical force in liphophilic polymer, forming thousand of un 
leachable microscopic drug reservoirs.(Ashok kumar.J, et, al., 2010) the dispersion is quickly 
stabilized by immediately cross linking the polymer chains in situ which produces a medicated 
polymer disc of specific area and fixed thickness. 
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                                  Figure: 4 Design of micro reservoir transdermal patches  
Drug in adhesive type transdermal patches 
   The drug and others selected excipients, if any, are directly incorporated into the 
organic solvent based pressure sensitive adhesive solution, mixed cast as a film and dried to 
evaporate the solvents, leaving a dried adhesive matrix film containing the drug and exicipents. 
This drug in adhesive matrix is sandwiched between release liner and backing layer. Drug-in-
adhesive patch may be single layer or multi layer. The multi layer system is different from single 
layer in that it adds another layer of drug-in-adhesive, usually separated by a membrane.  
(GeetaArrarwalet.al., 2009,Eseldinkeleb,et.al., 2011) 
   
                        Figure: 5 Design of adhesive type transdermal patches 
 Conditions which Transdermal patches are used 
 When the patient has intolerable side effects and who is unable to take oral medication 
and is requesting an alternative method of drug delivery. 
 Where the pain control might be improved by reliable administration. This might be 
useful in patients with cognitive impairment or those who for other reasons are not able 
to self medicate with their analgesia. 
 It can be used in combination with other enhancement stregiges to produce synergistic 
effects.(Vinod K,et,al.,2010) 
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Mechanism of drug delivery in transdermal drug delivery system 
   Transdermal absorption occurs through a slow process of diffusion driven by the 
gradient between the high concentration in the delivery system and the zero concentration 
prevailing in the skin. The delivery system must kept continuous contact with the skin for a 
considerable time. It is a formulation or device that maintains the blood concentration of the drug 
within the therapeutic window. The drug levels neither fall below the minimum effective 
concentration not exceeding the minimum toxic drug. 
    A transdermal drug delivery system is a device that is made of one or more types 
of polymers embedded with drugs to deliver the embedded drug through the skin over a period of 
time. In this delivery system with the patch and its different layers are involved.   
 
   
                                                    Figure: 6 Structure of skin permeation  
   The drug penetrate the skin obey’s the fick’s first law where steady-state flux (J) 
is related to the diffusion coefficient(D) of the drug in stratum corneum over a diffusional path 
length or membrane thickness(h), the partial coefficient(P) between the stratum cornuem and the 
vehicle and the applied drug concentration(C0) which is assumed to be constant. 
                                                        Dm/dt – J – DC0P/I 
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ANATOMY AND PHYSIOLOGY OF SKIN 
                        The skin is the major organ of the body making upto 16% of body weight, with a 
surface area 1.8cm
2
. 
          The most vital functions are to form a physical barrier to the environment, 
allowing and restrictive the inward and outward passage of water. It is protective obstruction that 
prevents internal tissues from exposure to trauma, ultraviolet radiation, temperature extremes, 
toxins and bacteria. 
   The anatomy of skin divided into three layers such as epidermis, dermis and fat 
layers. (Eseldinkelebet,al., 2011) 
Epidermis  
    The epidermis is the comparatively thin, tough, outer layer of the skin. The 
epidermis is made up of most of the cells of keratinocytes. The originate from cells in the deepest 
layer of the epidermis called basal layer. New keratinocytes receiving migrate up toward of the 
epidermis. After keratinocytes reaches the skin surface, they are slowly shed and are replaced by 
younger cells pushed up from below.(Tyagi.R.K,et,al., 2011) 
           
Figure: 7 Anatomy of skin 
                       The outermost portion of the epidermis is called stratum corneum. It is moderately 
water proof and when undamaged, prevents most bacteria, viruses and other foreign substances 
from entering the body. The epidermis is defensive the internal organs such as muscles, nerves 
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and blood vessels against trauma. In some of the body area obligatory superior production (such 
as palms of the hand and the soles of the feet), outer keratin layer of stratum corneum is much 
thicker. 
                        Scattered throughout the basal layer of the epidermis cells called melanocytes, 
which produce the pigment of melanin is one of the main contributor to skin color. The main 
function of melanin is to filter out ultraviolet radiation from sunlight, which damage DNA, 
resulting in various had effects, including skin cancer. 
   The epidermis is also containing Langerhan’s cells, which are the part of the 
skin’s immune system. These cells help detect foreign substance and defined the body against 
infections, they also play a role in the expansion of skin allergies. 
Dermis 
   The dermis is the skin of second layer or next layer of epidermis. It is the thick 
layer of fibrous and elastic tissues, these are gives the skin its flexibility and strength. The dermis 
contains nerve ending, sweat gland, oil glands, hair follicles and blood vessels. 
                        The nerve ending is response of sense of pain, tough, pressure and temperature. 
Some of area is contain more nerve ending than compare to other areas. The dermis contain 
another important glands are sweat gland. Sweat is composed of water, salt, and other chemicals. 
As sweat evaporates off the skin, it is help of cool the body. 
                       The sebaceous glands secrete sebum into hair follicles. Sebum is an oil that keeps 
the skin moist and soft and act as a barrier against foreign substance. The hair follicles generate 
the various types of hair throughout body. Hair not only contributes to a person’s appearance but 
has number of physical role, including body temperature and proving protection from injury, and 
enhancing sensation. The creation of hair follicle also contains stem cells capable of regrowing 
damaged epidermis. 
   The blood vessels of the dermis provide nutrients to the skin and help control 
body temperature. The heat makes blood vessels enlarge, allowing large amount of blood to 
circulate near the skin surface, where the heat is unrestricted. Cool make blood vessels narrow, 
retaining the body’s heat.(Tyagi.R.K,et,al., 2011) 
Fat layer 
   Below the dermis lies a layer of fat that fill the body from heat and cold, provides 
protective padding, and serves as an energy strong area. They contained living cells, called fat 
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cells, hold together by fibrous tissue. The fat layer varies in thickness, from a fraction of an inch 
on the eyelids to several inches on the abdomen and some of the body parts.(Tyagi.R.K,et,al., 
2011) 
Functions of the skin 
   There are many different structures within the skin. Together these structures are 
important protective properties to the skin that help to avoid damage to the influences. In this 
way, the skin:  
 Protection: an anatomical barrier from pathogens and damage between the internal and 
external environment in bodily defense; Langerhans cells in the skin are part of the 
adaptive immune system. 
 Sensation: contains a variety of nerve ending that react to heat and cold, touch, pressure, 
vibration, and tissue injury; see somaticsensory system and hap tics. 
 Heat regulation: the skin contains a blood supply far greater than its requirements which 
allows precise control of energy loss by radiation, convection and conduction. Dilated 
blood vessels increase perfusion and heat loss, while constricted vessels greatly reduce 
cutaneous blood flow and conserve heat. 
 Control of evaporation: the skin provides a relatively dry and semi impermeable barrier 
to fluid loss. Loss of this function contributes to the massive fluid loss in burns. 
 Aesthetics and communications: others see our skin and can assess our mood, physical 
state and attractiveness. 
 Storage and synthesis: act as a strange centre for lipid and water, as well as a means of 
synthesis of vitamin D by action of UV on certain parts of the skin. 
 Excretion: sweat contains urea; however its concentration is 1/130th that of urine, hence 
excretion by sweating is at most a secondary function to temperature regulation. 
 Absorption: the cells comprising the outermost 0.25-0.40mm of the skin thickness almost 
exclusive supplied by external oxygen”, although the “contribution to the total respiration 
is negligible”. In addition, medicine can be administered through the skin, by ointments 
or by means of adhesive patch, such as the nicotine patch or iontophoresis. The skin is an 
important site of transport in many other organisms. 
 Water resistance: the skin act as a water resistance barrier so essential nutrients aren’t 
washed out of the body. 
Department of pharmaceutics                                                                                    Introduction 
 
Nandha college of pharmacy, Erode 52. Page 21 
  
 
DISEASE PROFILE 
Introduction of diabetes mellitus 
   Diabetes mellitus is a disease caused by defective functioning of the cells of the 
islets of Langerhans in the pancreas. The secretion made by the pancreas is known as insulin. 
Insulin’s first is to help the body use glucose or sugar and when there is inadequate supply of 
insulin, the function of the body gets affected and very soon diabetes follows. The body loses its 
ability to metabolized sugar or it may develop because the body is producing too much of sugar. 
Diabetes is not a disease but a kind of disorder caused by inadequate supply as well as utilization 
of insulin in the body.  
Anatomy and physiology of Pancreas 
      Pancreas an exocrine and endocrine gland of about 12-15cm long and 2.5cm 
thickness connected by two small ducts to duodenum. The pancreas divided into three parts such 
as head, body and tail.It is the primary organ involved in sensing the organism’s dietary and 
energetic states via glucose concentration in the blood. The pancreas is soft, glandular organ. 
    The endocrine function is performed by clusters of cells the pancreatic islets, or 
islets of Langerhans that secrete the hormone insulin and glucagon into the blood. The exocrine 
tissues secretes digestive enzymes, these enzyme are secretes into a network of ducts that join the 
main pancreatic duct, which runs the length of the pancreas.  
   After a meal, Carbohydrated in food are converted into glucose in the intestine 
and liver and enters the blood stream- cells sense the rising the blood glucose level and secretes 
insulin into the blood to breakdown the glucose molecules. (Vivek Kumar Sharma et al.,2010) 
    Once it reaches the blood stream, insulin helps glucose to enter the body’s cells, 
where it can be “burned” by the liver and muscles for energy. Liver and muscles can also convert 
glucose to glycogen, a reverse form of energy that is stored there for future use. All three 
hormones are polypeptides. 
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Figure: 8 Physiology of Pancreas 
Types of diabetes 
There are three types of diabetes  
 Type 1 diabetes 
 Type 2 diabetes 
 Gestational diabetes 
Type 1 diabetes (Insulin dependent diabetes mellitus) 
   The result from the body’s failure to produce insulin, and a presently requires the 
person to inject insulin. It is otherwise called insulin dependent diabetes mellitus. In this type 
characterized by loss of the insulin producing beta cells of Langerhans in the pancreas leading to 
insulin deficiency. This type of diabetes can be further classified as immune-mediated or 
idiopathic. The majority of type 1 diabetes medicated nature, where beta cells loss T-cell 
mediated autoimmune attack. 
Type 2 diabetes (non insulin dependent diabetes mellitus) 
   In this type characterized by insulin resistant this may combined with relatively 
reduced insulin secretion. The responsiveness of body tissue to insulin is believed to involve the 
insulin receptors. In this type of diabetes the most common type. It is also called as non-insulin 
dependent diabetes mellitus. 
 
 
Department of pharmaceutics                                                                                    Introduction 
 
Nandha college of pharmacy, Erode 52. Page 23 
  
Maturity-Onset diabetes of the young 
   When present in the youngsters, non insulin dependent diabetes mellitus is often 
referred to as maturity onset diabetes of youth. This is the type of spontaneous diabetes and may 
be due to genetics of β cell function.   
                               In this group, a ketosis-resistant, non insulin dependent, generally 
asymptomatic form of diabetics is present in individuals before age of 25.  
Gestational diabetes mellitus 
   This is resembles type 2 diabetes in several respects, involving a combination of 
relatively inadequate insulin secretion and responsiveness. It occurs in about 2%-5% of all 
pregnancies and many improve or disappear after delivery. It is fully treatable but requires 
careful medical supervision throughout the pregnancy. About 20%- 50% of affected women 
develop type 2 diabetes later in life. 
                       It may be transient, untreated gestational diabetes can damage the health of the 
fetus or mother. This is risk to the baby include macrosomia (high birth weight), congenital 
cardiac and central nervous system a nomalies and skeletal muscle malformations. Increased 
fetal insulin may inhibit fetal surfactant production and cause respiratory distress syndrome. 
Hyper bilirubinemia may result forms red blood cells destruction. (Vivek Kumar Sharma et al., 
2010) 
Signs and symptoms 
The classical symptoms of diabetes are 
 Polyuria (frequent urination),  
 Polydipsia (increased thirst),  
 Polyphagia (increased hunger).  
 Diabetic keto acidosis (Diabetic coma) 
Ketoacidosis of different grades generally occurs in insulin dependent diabetes. The most 
common cause is infection. Others are trauma, stroke, pancreatitis, stressful conditions and 
inadequate doses of insulin.(www.rxlist.com) 
The other symptoms of diabetes mellitus are such as dehydration, weight loss, nausea, vomiting 
and infections of the bladder. 
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Blood glucose level 
   Blood glucose i.e is the amount of glucose present in the blood. It is otherwise 
called as serum glucose level. The amount of glucose present in the blood is expressed in milli 
mol/liter. Normally blood glucose level is higher in time of after meal and lowers at morning.  
Normal blood glucose level  
                                Before meal:  4 mmol/L or 72mg/dl 
                                After meal:    7.8 mmol/L or 140mg/dl 
If the person suffering with diabetics Mellitus has the blood glucose level out of this range. 
Drugs used for anti diabetic 
 Insulin 
   Insulin is consisting of two polypeptide disulfide bonds. Insulin was the first of 
these hormones to be discovered. Insulin in diabetes mellitus was immediately recognized, and 
clinical use of insulin in the treatment of this disease began almost immediately after its 
discovery. Diabetic patients are depending on insulin for the management for diabetics. Without  
insulin, they develop degenerative complications like microangiopathy, nephropathy, 
retinopathy. (Leonard Tedong et.al.,2006). 
Major role of insulin are as follows: 
 It facilities the passage of glucose through cell barriers into the cells. 
 It effects the phosphorylation of glucose.  
 It also plays role in oxidative phosphorylation. 
 It is essential to lipid and protein catabolism. 
Oral hypoglycemic agents 
Sulfonyl urea 
   These are dived into two types:  
 First generation Drugs              Tolbutamide 
                                                                        Chlorpropamide 
Second generation drugs                                Glipizide 
                                                                        Gliclazide 
                                                                        Glimepiride 
Department of pharmaceutics                                                                                    Introduction 
 
Nandha college of pharmacy, Erode 52. Page 25 
  
Biguanides                                                     Phenformin                                                                                                
                                                                        Metformin 
Meglinitides analogues                                  Repagilinide 
                                                                        Nateglinide 
Thiazolidinediones                                        Rosiglitazone                                                                                              
                                                                        Pioglitazone 
α-Glucosidase inhibitors                               Acarbose 
                                                                        Miglitol 
Sulfonylureas 
   The act to force the pancreas to produce more insulin which then lowers the blood 
sugar level. For this medication the pancreas should at least produce some insulin. If pancreas 
not making insulin then this type of medication is not suitable and if patients suffering from 
allergy to sulpha drug then sulfonylureas have to be stopped. 
   The principle mechanism is decreased hepatic glucose output and increased 
uptake of glucose in muscles. High affinity receptors for sulfonylureas are present on the KATP 
channel activation causes depolarization,Ca
2+  
entry and insulin secretion. 
Side effects 
 Hypoglycemia 
 Stomach upset 
 Skin rash and itching  
 Weight gain 
 
 
Biguanides 
    It works by inhibiting the production and release of glucose from the liver. One of 
the benefits of biguanides is to reduce the weight gains and which helps to the lowering the 
blood glucose level. Enhance the peripheral tissue and in skeletal muscle. It  also reduce the low-
density lipoproteins. 
Side effects 
 Metal taste in mouth 
 Nausea 
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 Stomach problem 
Meglinitides 
    They help to make more insulin by the pancreas right after meal. The very 
good thing about they act very fast and the body uses it quickly to reduce the blood sugar level.If 
one medicine alone does not control the blood sugar, doctor prescribe it along with Metformin to 
have good therapeutic effect. 
Side effects: 
 Weight gain 
 Low blood sugar level 
Thiazolidiendiones 
   This medication works by making the cells more sensitive to insulin thus insulin 
can help to move glucose from the blood stream to the body cells for the energy production. 
   They also reduce the peripheral insulin resistance leading to reduction of blood 
glucose concentration. While taking this medication the enzyme level should be checked 
regularly. The reduction in blood glucose is often accompanied by reductions in circulating 
insulin and free fatty acids. Triglycerides may decline with little alteration in LDL: HDL ratio. 
Side effects: 
It affects the liver function and leads to nausea, vomiting, tiredness 
 Yellowing of skin or whiteness of eye 
 Dark colored urine 
 Weight gain 
 Swelling in legs or ankles 
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α-Glucosidase inhibitors 
   This medication blocks the enzymes in the digestive system that is responsible for 
the breakdown of starch that we eat. The sugar produced is absorbed slowly and is responsible 
for the prevention of rise in blood sugar level throughout the day. 
Side effects: 
 Loose stools 
 Abdominal pain and bloating 
 Flatulence 
   Alternative therapy to the current modern pharmacotherapy of Diabetes Mellitus 
is urgently required, because of the inability of existing to control all the pathological aspects of 
the disorder. 
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Literature Review 
 
Literature review of proniosomes 
Ankurguptha et al., has investigated proniosomal carriers system used for the treatment of 
anti hypertension activity. These carriers having able delivering entrapped drug over period 
of long time. The potential of proniosomes were introduced in transdermal drug delivery 
system was investigated by encapsulating the drug of proniosomal gel composed of different 
ratio of sorbiton fatty acid esters, cholesterol, lecithin prepared by phase conservation 
method. The formulated proniosomal gel was characterized in vitro studies such as size, 
vesicle count, drug entrapment, drug release profile and vesicular stability at different storage 
conditions. Stability study for pronisomal gels were carried out for four weeks.  Resulted 
proniosomes in a encapsulation yield of 66.7-78.7 %. Proniosomes were characterized by 
transmission electron microscopy. In vitro studies showed prolonged release of entrapped 
captopril. At cool or refrigerated condition, higher drug retention was observed. 
Chandra et al., has investigated in piroxicam used as potent non steroidal anti-inflammatory 
drug, with due potential for dermal delivery. Permeation activity of piroxicam was resolute 
from proniosome based reservoir type transdermal gel formulation across excised rat 
abdominal skin by using keshery chein diffusion cell. There was extensive improvement 
Influx over the control gel formulation. The lipid vesicle was investigated entrapped drug and 
vesicle size of niosomes was formed. In this study observed span 60 based formulation 
produced vesicle smallest in size but higher entrapment efficient while those of span 80 
produced vesicle least entrapment efficiency. Proniosomes were prepared by conventional 
technique and used maltodextrin and sorbital as base. The morphology of proniosomes was 
studied by scanning electron microscopy. Maximum flux achieved for transdermal system 
based on proniosomal gel compared to control gel. 
SanjulaBaboota et al., has developed a low dose of proniosomal gel celecoxib was used in 
the treatment of osteoarthritis. All the prepared formulations were concerned to 
physicochemical evaluations and anti inflammatory studies. The efficient entrapment was 
>90%. The vesicle shape was determined by transmission electron microscopy. The vesicle 
size, size distribution and poly dispersive studies were performed by photon correlation 
spectroscopy. Anti inflammatory studies were performed using the rat hind –paw oedema 
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induced by carrageenan (1%w/w).  The particular proniosomal gel produced 100% inhibition 
of paw oedema in rats upto 8 hours after carrageenan injection. It produced 95% and 92% 
inhibition after 12 and 24 hours respectively. These results indicate that proniosomes were a 
promising carriers for the transdermal delivery of celecoxib. The large dose of proniosomal 
gel was produce adverse effect. 
Ibrahim Alssara et al., has evaluated the transdermal potential of niosomes bearing a potent 
anti inflammatory piroxicam. Piroxicam loaded niosomes were prepared and characterized 
for surface morphology and entrapment efficiency. The in-vitro evaluation of different 
proniosomal gel was carried out by the Franz diffusion cell. The different non ionic 
surfactants were used to produce optimum encapsulation efficiency. The prepared 
proniosomes were significantly enhanced drug permeation and reduced lag time (p<0.05). 
The piroxicam prepared with span60 produced higher permeation flux across the skin than 
compare to the tween 80. The span60 produced higher release rate than compare to span20 
and span80. But niosomes prepared by Tween produced higher release rate than compare to 
span. This result indicates lipophilicity and hydrophilicity of surfactant has main role release 
of piroxicam. The particle size of proniosomes was determined by scanning electron 
microscopy. The encapsulation efficiency of proniosomal gel was evaluated by High 
performance liquid chromatography method. Niosomes formed from span and tween exhibit 
very high encapsulation efficiency.  
Rishukakar et al., has investigated a number of novel drug delivery systems had emerged 
encompassing various route of administration to produced controlled and targeted drug 
delivery. Encapsulations of the in vesicular form to produce prolong the existence of drug 
release in systemic circulation and reduced toxicity. In this study to developed number 
vesicular drug delivery system such as liposomes, niosomes, Transferosomes, ethosomes and 
proniosomes etc. In this study proniosomes are water soluble carrier that are coated with 
surfactant and can be hydrated to form niosomal dispersion immediately before use on brief 
agitation on hot water. In this study, review the proniosomes were prepared and evaluate the 
characterization of proniosome and study of penetration and transport of various drug though 
skin. 
Walve et al., has developed proniosomes are formed by using suitable carrier coated with 
nonionic surfactant and can be converted into niosomes immediately before use by hydration. 
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These types of proniosomes minimize the problem of niosomes physical stability such as 
aggregation, leakage and fusion, and provide convenience of transportation, distribution, 
storage and dosing. This proniosomes derived niosomes are so good as than compare to 
conventional niosomes. In this review bring out proniosomes are preparation, 
characterization, entrapment efficiency, in-vitro drug release application and merit. 
Thejaswi et al., has developed proniosomes derived niosomes form, niosomes are made 
from nonionic surfactant vesicle entrap a solute in manner analogous to liposomes. They are 
osmatically active, stable and increase the stability of the entrapped drugs. In this describe 
the formulation and evaluation of proniosomes.  
Hanan Ei-Laithy et al., has developed novel sustained release proniosomal system  designed 
using the sugar esterase  as non-ionic surfactant in which proniosomes converted to niosomes 
upto hydration following topical application under occlusive condition. All formulae 
exhibited high entrapment efficiencies, regardless of the surfactant HLB. Vesicle size within 
range from 0.63µm-2.52µm these are effect for the transdermal drug delivery system. The 
extant absorption proniosomes was larger when compare to oral tablet the bioavailability also 
increase. Histopathological evaluation revealed only moderate skin irritation when using SEs 
compared to the skin inflammation when using Tween 80.Sugar esterase proniosomes may 
be effective carrier for vinpocetine. 
Sudhamani et al., has investigated ibuprofen loaded maltodextrin based proniosomes .These 
were prepared by slurry method with different surfactant and carrier ratio.The formulation 
and evaluation for FT-IR study and scanning electron microscopy. The niosomal dispersion 
was further evaluated for entrapment efficiency, in-vitro study, kinetics data analysis, 
stability study. The result from SEM analysis has given smooth surface of proniosomes. The 
formulation F4 which showed higher entrapment efficiency of 96.57±1.08% and in-vitro 
cumulative drug release of  92.16% at the end of 12 hr was found to be best among the all 9 
formulations. Release was best explained by the zero order kinetics. Kinetics analysis 
showed that the release follow non-fickian release. Proniosome formulation has showed 
appropriate stability for 60 days by formulations at different condition. 
Ajay solanki et al., has developed preparation, optimize and characterize ketoprofen 
proniosomes. The niosomes were prepared using a slurry method followed by in vitro 
evaluation after embedding the proniosomes derived niosomes into a carbopol matrix. The 
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central composite box-wisondesing was used for the optimization with the total lipid 
concentration(X1), surfactant loading9(X2), and amount of drug(X3) as the independent 
variables. Prepared proniosomes were characterized for percentage entrapment and mean 
volume diameter. Multiple regression analysis and contour picts were used to relate the 
dependent and independent variables. Checkpoint batches were also preparaed to prove the 
validity of the evolved mathematical model and contour plots. The optimizations predict the 
levels of X1, X2, X3 for a maximized response of PDE witjconsrians of ≤ 5 µm on MVD. 
Optimized batch was used to prepare a niosomal gel, which showed significantly higher 
cumulative amount of drug permeated and steady state transdermal flux compare to pain gel. 
This work has demonstrated the use of the central composite Box wlson design, regression 
analysis and contour plots in optimizing ketoprofen proniosomes. Niosomal gel formulation 
has also demonstrated permeation enhancement ketoprofen compared to pain gel. 
IntakhabAlam et al., has developed low dose of  proniosomal gel containing celecoxib used 
in the treatment of osteoarthritis.The prepared formulations were subjected to 
physiochemical evaluation and anti- inflammatory studies. The entrapment studies were 
carried out > 90%.The vesicle shape can be determined by transmission electron microscopy. 
The vesicle size, size distribution and poly dispersity studies were performed using photon 
correlation spectroscopy. Anti inflammatory studies were performed using the rat hind-
powoedema induced by carrageen injection. The selected proniosomal gel was produced 
100% inhibition of powoedema in rat’s upto 8 hours after carrageen injection. It induced 
95% and 92% inhibition after 12 hours and 24 hours respectively. These result was effective 
for pronisomal transdermal preparation of celecoxib. Thus celecoxib can be formulated into a 
low dose proniosomal gel that can save the recipient from the adverse effect of large dose. 
Deenanathjhade et al., has investigated formulation and evaluation of vesicular drug 
delivery carrier system proniosomal gel for transdermal delivery of antifungal agent, 
griseofluvin. Proniosomal gel formulations of griseofluvin were prepared and characterized 
for vesicular shape, size, entrapment efficiency and drug permeation across pig ear skin. The 
optimized proniosomal gel formulation showed enhanced in vitro skin permeation greater as 
compared to plain drug solution in water. The result was optimized proniosomal gel 
formulation of griseofluvin better skin permeation potential than plain drug solution in water. 
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 Jia- You Fang et al., has investigated estradiol from different proniosomal gel formulations 
across excised rat skin. The encapsulation efficiency and size of niosomal vesicles formed 
from pronisomes by hydration. The encapsulation of proniosomes with span surfactant 
showed very high value. Proniosomes with surfactant the permeation estradiol across the 
skin. Both permeation enhancer effect of non ionic surfactant and vesicle- skin interaction 
may produce to the mechanism for proniosomes to enhance estradiol permeation. Niosomal 
suspension and proniosomal gel showed different behavior in modulating transdermal 
delivery of estradiol across the skin. Presence or absences of  cholesterol in lipid bi layers of 
vesicle did not reveal difference in encapsulation and permeation of the associate estradiol. 
The types and content of  non ionic surfactant proniosomes are important factor affecting the 
efficiency of transdermal estradiol delivery.  
 
Mahmoud Mokhar Ahmed Ibrahim et al., has investigated to formulate and evaluate 
proniosomal transdermal carrier system for flurbiprofen. Proniosomes were prepared by 
various non- ionic surfactants such as span 20,span 40, span 60, and span 80 without and 
with cholesterol at percentage ranging from 0%to 50%.The effect of cholesterol and 
surfactant type and drug content were investigated. Drug release through cellophane 
membrane and rabbit skin. Drug release from the prepared system was compared to that from 
flubiprofen suspension in distilled water and HPMC gel. By addition of span 20, span 80 into 
the amount of cholesterol affected the preparation type to be either proniosomal alcoholic 
solutions or liquid crystalline gel system. And other type span 40, span 60 produced gel 
system in presence or absence of cholesterol. The proniosomal composition controlled drug 
diffusion rate to either faster or slower than prepared flurbiprofen suspension in HPMC gel or 
distilled water, respectively.  
Nand Kishore et al., has developed proniosomal gel as non-ionic surfactant based vesicle 
system which exits in different liquid crystalline phase. The formation proniosomal gel by 
mixing of surfactant in alcohol and limited hydration with aqueous phase.The various phases 
of liquid crystalline structure can be utilized as such for topical/transdermal applications or 
can be used after further hydration to form niosomes. Interaction studies between proniosome 
components and reports the delivery of therapeutic agents through topical/dermal route, but 
cosmetic application were not much explored.  
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Rishukakkar et al., has developed valsartan proniosmal gel prepared by phase coacervation 
method. The prepared formulations were characterized for encapsulation efficiency, vesicle 
size, shape and in vitro release. Stability study was carried out to investigate the leaching of 
drug from the proniosomal system during storage. The result showed that valsartan in all the 
formulation was successfully entrapped and a substantial change in release rate and an 
alteration in the encapsulation efficiency of drug from proniosomes were observed upon 
varying the type of cholesterol content. The encapsulation efficiency of proniosomes 
prepared with span 60 is very effective for span40.Apreparation with 9:2:9 ratio of span 60, 
cholesterol, lecithin gave maximum encapsulation efficiency and release report also highest 
then compare to other compositions. Proniosomal formulations showed fairly high retention 
of valsartan inside the vesicles at refrigerated temperature upto one month. 
Sankar et al., has approach to stabilize niosomal drug delivery system without affecting its 
properties of merits have resulted in the development of the promising drug carrier, 
proniosomes. Proniosomes is dry formulation using suitable carrier coated with non ionic 
surfactant can be converted into niosomes immediately before hydration. These proniosomes 
derived form of niosomes are as good as or even better conventional niosomes.  
Akhilesh et al., has developed based on nanotechnology is one of the advancement in 
nanotechnology is the preparation of pronisomes –derived niosomes are solid colloidal 
particles which may be hydrated immediately before use to yield aqueous noisome dispersion 
similar to those produced by more cumbersome conventional methods. These proniosomes 
are more physical stable than compare to niosomes. The physical stability such as 
aggregation, fusion and leaking and provide additional convenience in transportation, 
distribution, storage and dosing. The addition of  proniosomes-derived to niosomes  are 
described in terms of their morphology, particle size, particle size distribution and drug 
release. A slurry method has to be produced proniosomes using maltodextrin as the carrier. 
The encapsulation is dependent on the amount of maltodextrin used. 
Kiran Yadav et al., has developed proniosomal gel as a provesicular approach for 
transdermal drug delivery. The skin has a very tough diffusion barrier that is lipid bilayer in 
the stratum corneum inhibiting penetration of drug moiety which is rate limiting barrier for 
penetration barrier. They may act as vehicle or as permeation enhancer for bioactive 
materials to enhance their penetration via stratum corneum. Proniosomal gel are semisolid 
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liquid crystal product of nonionic surfactant easily prepared by dissolving the surfactant in a 
minimal amount of an acceptable solvent and the least amount of aqueous phase. 
Proniosomal gel offers a great potential to reduce the side effects of drug and increased 
therapeutic effectiveness. Proniosomes can entrap both hydrophilic and hydrophobic drugs.    
Literature review of Transdermal patchs 
PandyaNarendra et al., has investigated glipizide transdermal patchs of matrix type using the 
Eudragit RL 100 and Eudragit RS 100 by the mercury substrate method. This were evaluated 
various in vitro parameters (Thickness, Folding Endurance, Moisture content, Moisture uptake, 
drug content, drug permeation, scanning electron morphology).Drug content of patchs had more 
than 98%.In vitro permeation study was found to be Franz diffusion cells. Variations in drug 
permeation profile were observed among various formulations. The SEM of patch showed the 
formation of porous surface after in vitro permeation study. The drug and polymer interaction 
results suggested on interaction between drug and polymer was observed. From formulations, 
formulation M3 was selected for the best formulation and formulation was stable for period of 90 
days stability study. 
Arijit das et al., has developed prepare and evaluate transdermal drug delivery of metformine 
HCL. The drug undergoes rapid first pass metabolism which necessitates its frequent dosing by 
oral route. Transdermal drug delivery system of the drug was prepared using combination of a 
hydrophobic polymer, ethyl cellulose and hydrophilic polymer, polyvinyl pyrrolidine in different 
ratios by solvent evaporation technique. Polyvinyl alcohol was used to prepare the backing 
membrane and dibutyl phthalate as plasticizer. The prepare patches were characterized for 
various physiochemical parameters like film thickness, tensile strength, moisture content, 
moisture uptake, water vapor transmission rate. Permeation studies were carried out for patch 
through commercial semi permeable membrane as well as rat abdominal skin using keshary-
chein diffusion cell and selected ex vivo skin permeation and drug release from the patch and 
release data of selected patch showed good fit into higuchi equation. 
Debjit Bhowmik et al., has developed transdermal delivery system produce sustained release as 
well as reduced the intensity of action and reduce the side effects associate with oral therapy. It 
delivers the drug through intact the skin at a controlled rate into the systemic circulation. The 
deliver rate of drug is controlled by the skin or membrane in the delivery system. Formulated 
drug to meet specific biopharmaceutical and functional characteristics. The material of 
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construction, configuration and combination of the drug proper cosolvent, excipient, penetration 
enhancer and membrane are carefully selected and matched to optimize adhesive properties and 
drug delivery required. Transdermal drug delivery-an approach used to deliver drugs through 
skin for therapeutic use as an alternative to oral, intravascular, subcutaneous and transmucosal 
routes. Transdermal delivery system used for different treatment of disorder of hormone 
replacement therapy, management of pain, angina pectoris, smoking cessation and neurological 
disorder such as Parkinson’s disease. It should not cause any skin irritations and sensitization. 
Enhancing the bioavailability via bypassing first pass metabolism.    
 
Ashok kumar et al., has investigated 74% of drug are taken orally and are not to be as effective 
as desired so to improve such character for the transdermal drug delivery system. This system is 
very effective than compare to the traditional topical drug delivery. TDDS are dosage involves 
drug transported to viable epidermal and dermal tissue of the skin for local therapeutic effect 
while a very major fraction of drug is transport into the systemic blood circulation. The adhesive 
of the transdermal drug delivery system is critical to the safety, efficacy and quality of the 
product. This system is more advantage than compare to other dosage system such as limitation 
of hepatic first pass metabolism, enhancement of therapeutic efficacy and maintain of steady 
plasma level of drug. In this article provide an overview of types of transdermal patch, method of 
preparation and its physicochemical methods of evaluation. 
Sharavani et al., has to be developed formulate and characterized Fulvestrant reservoir type 
transdermal drug delivery. It is very effective for breast cancer cells by down regulates the ER 
Protein in human breast cancer cells. It has demonstrated the drug can be administrated though 
transdermal application with predetermined targeted release. The formulation was evaluate by 
FT-IR study and evaluate in vitro study also. The data obtained from in vitro skin permeability 
studies is fitted with kinetics models to determine drug release mechanism and it was find about 
drug release pattern follow zero order kinetics. It has been demonstrated that targated 
concentration has been achieved in the in one of the formulation tested and conducted in vivo test 
also.   
Roongnapa Suedee et al., has to be developed a transdermal patch for selective controlled 
delivery of the active S-enantiomer from racemic proponolol. The drug was added to the 
chitosan gel, This was exhibit high flux and had the ability to encaustic selective delivery S-
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propranolol across excised rat skin. The reservoir patch for enantiomer controlled delivery of 
propranolol was therefore fabricated by incorporating the chitosan gel formulation containing 
racemic proparnolol HCL into the MIP composite membrane Laminated backing. From this 
formulation, evaluate the pharmacokinetic parameters in rats. S-propranolol enantiomer plasma 
concentration profiles for the transdermal in the in vivo study were comparable to data for the gel 
formulations that were applied directly to skin, and containing a single S-enantiomer of 
propranolol. The results demonstrate that the transdermal patch based on MIP composite 
membrane controlled release system may have potential in the enantio selective controlled 
delivery of the S-isomer of racemic propranolol. 
Geeta aggarwal et al., has to be investigated in Transdermal drug delivery established itself as 
an integral part of novel drug delivery system. Transdermal delivery is polymeric formulations 
which when applied to skin delivery the drug at a predermined rate across dermis to achieve 
systemic effects. Transdermal patch dosage form is costly than compare to conventional 
formulation, but it is very popular because of their unique advantages. The discontinue drug 
administration by simply removing the patch from the skin are some of the potential advantage 
of transdermal drug delivery. 
Srinivas Mutalik et al., has developed the membrane moderated transdermal system were 
prepared using drug containing carbopol gel as reservoir and different rate controlling 
membranes. The possible drug interaction between drug and polymer was studied by IR 
spectroscopy, DSC and HPTLC analysis. In vitro release, histopathological test and 
pharmacokinetics evaluation were carried out in mice. 
Divyesh patel et al., has improve characters of transdermal drug delivery system. Drug achieve 
systemic effect differs from traditional topical drug delivery to transdermal drug delivery system. 
In this delivery system drug transport viable epidermal to dermal tissue of the skin for local 
therapeutic effect while a very major fraction of drug is transported into systemic circulation. 
The adhesive of the transdermal drug delivery system critical to the safety, efficacy and quality 
control of the product.IN this system having several advantages such as limitation of hepatic first 
pass metabolism, enhancement of therapeutic efficacy and maintenance of steady state. 
Kuan-Hung et al., has developed reservoir type fentanyl transdermal drug delivery system using 
ethanol, in this ethanol acting as a skin permeation enhancer and an important quality control 
component. Samples were extracted with water by ultrasonic vibration using acetone as the 
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internal standard. This method was fully validated according to the ICH Q2A and Q2B 
guidelines. The robustness and system suitability testing were conduct. A validated method for 
the assay of ethanol in reservoir-type fentanyl transdermal patchs was applied to quality control 
practices.    
Literature Review of vesicular system 
Kavitha et al., has investigated various type lipid based vesicular system having in controlled 
and targeted drug delivery system. Pharmacosomes bearing more advantages over liposomes and 
niosomes have come up as potential alternative to conventional vesicles. These were the 
amphiphilic phospholipids complexes of drug active hydrogen bind phospholipids. In this 
method is very useful delivery of drug directly to the site of infection, reduced toxicity, no 
adverse reaction and effective Biopharmaceutical properties of the drug and improved 
bioavailability of poorly soluble drugs. This system used in non-steroidal anti-inflammatory, 
cardiovascular and anti neoplastic drugs. 
Rishu Kakar et al., has investigated the number of novel drug delivery system have emerged 
encompassing various routes of administration to achieve controlled and targeted drug delivery. 
Encapsulated of the drug used in vesicular structure can produced to prolong the existence of the 
drug in systemic circulation and reduced the toxicity. The number of vesicular system such as 
liposomes, niosomes, transferosomes, ethosomes and proniosomes were developed. Proniosomes 
are water soluble carrier particles that are coated with surfactant and can be hydrated to form 
niosomal dispersion immediately before use on brief agitation in hot aqueous solutions.  
Parthiban et al., has developed colloidosome drug delivery the focus on the types, properties, 
fabrication techniques, characterization and stability of collodosomes. It is one of the type of 
vesicular system. The other recent developments number of lipid based system like liposomes, 
liposheres, niosomes, ethosomes, transferosomes are developed. The collodosomes are also 
solved the problem of insolubility, instability, rapid degradation, and widely used in specialized 
areas like proteins delivery, gene delivery, targeting to brain, tumour targeting. The more 
advanced system than compare to other vesicular system. The vesicular system reduces the cost 
of therapy by improved bioavailability of medication, especially in case of poorly soluble drug. 
In this system have a great, encapsulation efficiency with a wide control over size, permeability, 
mechanical strength and compatibility.   
Department of pharmaceutics                                                                                 Literature review   
 
Nandha college of pharmacy, Erode-52. Page 38 
 
Biju et al., has investigated about novel drug delivery system to deliver the drug at a rate 
directed by the needs of the body during the periods of treatment and channel the active entity to 
ths site of action. The number of novel drug delivery system is used as a controlled and targeting 
drug delivery. Encapsulation vesicular system in a drug vesicular structure which can predict 
prolonged and existence of the drug in systemic circulation, and reduce the toxicity. Liposomes, 
Niosomes, Proniosomes, transfersomes, pharmacosomes were developed. Advances have been 
made in the area of vesicular drug delivery, leading to development allow drug targeting and 
sustained or controlled release of conventional medicines.    
Satishshilpi et al., has developed colloidal and nanoparticulate carrier system in the biochemical 
field used in diagnosis, treatment, and disease management. Carrier system (liposomes, 
polymeric particles, micro emlusion droplets) are used for sustained release of drugs. These 
systems are used in the area of targeting to brain, tumor targeting and oral vaccine formulation 
problems associated stability and permeability.  
Surendar verma et al., has developed nanoparticle vesicular system like liposomes, niosomes 
etc. A nanomaterial is a material with one or more external dimensions or an internal structure, 
on the nano scale which could exhibit novel characteristic. These micro or nano structures are 
containers loaded with drugs which are ideal for sustained and targeted release of drug. Drug 
efficacy depends upon the drug loaded into vesicle, temperature, drug solubility P
H
, release 
characteristics, additives and most significantly, the vesicle morphology. 
Literature review of drugs 
Kajal ghosal et al., has investigate the effect of chemical enhancers on the release of glipizide 
through transdermal patch using different chemical enhancers. L – menthol, oleic acid and n – 
octanol were used in glipizide matrix patch. These were used in different ratios. To prepare the 
transdermal matrix patch, ethyl cellulose and poly vinyl pyrrolidone were used as polymer. Di – 
butyl phthalate was used as plasticizer at 30% concentration of the total polymer weight. These 
transdermal patches were evaluated for drug release. 
Shankar et al., has developed the membrane controlled transdermal system of glipizide and to 
evaluate with respect to various in vitro parameters. The membrane moderate transdermal system 
were prepared using drug containing carbopol gel as a reservoir and Eudragit RS-100(ERL), 
Eudragit RL-100(ERS) and poly(ethylene-co-vinyl acetate rate controlling membranes. The 
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membrane was prepared by solvent evaporation mercury subtract method. The drug permeation 
is depending upon the different rate controlling membrane.    
Subash et al., was formulate transdermal patch of glipizide which is a potent antidiabetic drug 
by using different ratio of polymers like hydroxyl methyl cellulose and Eudragit. These patches 
were prepared by solvent casting method. The polymers were prepared by different ratio with the 
drug was determined. The prepared transdermal patches were uniform in shape and white in 
color which was calculated for physicochemical characteristics, in-vitro release and in-vivo drug 
release in mice. 
Narasimha Rao et al., has investigated transdermal route is advantages over conventional 
modes of drug administration. It should be avoid hepatic first pass metabolism and improves 
patient compliance. The highly organized structure of stratum corneum forms effective barrier to 
the permeation of drug, which must be modified if poorly penetrating drugs to be administered. 
The use of chemical penetration enhancers would significantly increase the number of drug 
molecules suitable for transdermal delivery.   
Sampath kumar et al., in this formulation developed the hydrodynamic balanced controlled 
drug delivery system of glipizide. Ii should be increased the bioavailability and reduction of 
dosing frequency. The can added to the different polymers such as carbopol, HPMC, citric acid. 
These tablets were prepared by the direct compression method and evaluated to the drug content, 
invitro drug release dissolution. Buoyancy. 
Biraju patel et al., has developed direct compression method. Two superdisintegrants viz 
crospovidone and croscarmellose sodium with different binders viz PVP k-30 and pregelatinized 
were used. The formulation was evaluated by hardness, friability, disintegration, wetting time, 
drug content and invitro dissolution study. The selected formulation was compared to the 
conventional formulation. The  stability study on the optimized formulation indicated that there 
is no significant changes found in physical appearance, disintegration time and wetting time of 
the tablets. 
Shivalingam et al., has developed poorly water soluble drug used in solid dispersion technique 
by solvent evaporation method. The drug and carrier were in different ratios like 1:1, 1:2, 1; 3 by 
keeping constant weight. The prepared formulations were evaluated by phase solubility, in-vitro 
dissolution study ad evaluate drug and polymer interactions by FTIR method. 
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Bhosale Ashok et al., has investigated to enhace the solubility and impart a controlled release in 
a single formulation. The formulation was prepared by drug complex with β-cyclodextrin. Phase 
solubility studies were performed according to method reported by Higuchi and Connors. 
Inclusion complex of glipizide with  cyclodextrin is prepared by kneading and evaluated for in-
vitro release and FTIR spectroscopy. Glipizide was increasing concentration of polyethylene 
oxide and evaluated various tablet properties and invitro dissolution studies.          
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     DRUG PROFILE 
Name: Glipizide 
Synonym: Glipizida, Glydiazinamide 
Chemical name 
 1- cyclohexyl-3-[[p-[2-(5-methyrpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea. 
Molecular formula  
C21H27N5O4S 
Molecular weight 
445.55 
Structural formula 
                      
                         Structure of Glipizide 
            
 
Chemical property      
 P
Ka
- 5.9 
Categories       
             Hypoglycemic agent 
 
S.NO PHYSICAL PROPERTIES DESCRIPTION 
1. Description Whitish, odorless powder 
2. Solubility Insoluble in water and alcohol 
Soluble in 0.1N NaOH  
Freely soluble in dimethyl foramide 
3. Melting point 208
0
-209
0
C 
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Half life: 
                        2-5 hours 
Dose:                           
2.5-5 mg (www.drugbank.com) 
Mechanism of action 
                           Glipizide to produce lower blood glucose acutely by stimulating the 
release of insulin from the pancreas, an effect dependent upon functioning beta cells in the 
pancreatic islets. On the pancreatic cell membrane is cause depolarization by reducing 
conductance of ATP sensitive K
+ 
channels. This enhances Ca
 2+ 
influx degradation. 
(www.drugbank.com). The rate of insulin secretion at any glucose concentration is increased. 
Extrapancreatic effects also may play a part in the mechanism of action of sulfonylurea 
hypoglycemic drugs. Two extrapancreatic effects shown to be important in the action of glipizide 
are an increase in insulin sensitivity and a decrease in hepatic glucose production. However, the 
mechanism by which glipizide lowers blood glucose during long-term administration has not 
been clearly established. Stimulation of insulin secretion by glipizide in response to a meal is of 
major importance. The insulinotropic response to a meal is enhanced with Glipizide 
administration in diabetic patients. The postprandial insulin and C-peptide responses continue to 
be enhanced after at least 6 months of treatment. 
Pharmacokinetic 
                                Elimination half life:                          2-5 hr 
                                Duration of action:                             12-18 hr 
                                Clearance route:                                  Liver 
                                Daily dose:                                            5-20mg 
                                No of dose per day:                              1-2 
                                Elimination ranges:                              2-4 hr 
                                Peak plasma level:                               1-3 hr 
                               Apparent volume of distribution:       11 li 
                                Bioavailability:                                     98% 
                                Bound to plasma protein:                    98-99% 
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Side effect 
           Diarrhea, Headache, Constipation, Sore throat, Fever, chills, Dizziness, Fainting, 
Rash, Itching, heart palpitations, shortness of breath, chest pain. (www.alldrugs.com, 
www.rxlist.com) 
Drug interactions 
             Glipizide interaction with other drug have some fatal effects to the body. 
 Seizure medicines 
 Steroids 
 Isonoazid 
 Phenothiazines 
 Birth control pills and others hormones 
 Thyroid medicines 
 Niacin 
 Medicines to treat asthuma, colda or allergies 
 Diet pills 
 Heart or blood pressure medication such as nifedipine, verapamil, 
ditiazem. (www.alldrugs.com) 
Overdose 
                                  Over dose of glipizide, can produce hypoglycemia. Mild hypogilycemic 
symptoms without loss of consciousness or neurologic findings should be treated aggressively 
with oral glucose and adjustments in drug dosage and/or meal patterns. Severe hypoglycemic 
reactions with coma, seizure or neurological impairment occur infrequently. www.alldrugs.com 
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      SURFACTANT PROFILE 
Synonym                 
 Sorbitan mono octadecanoate, Sorbitan stearate  
Chemical name       
Sorbitan mono stearate (Span60) 
Molecular formula           
 C24H46O6 
Molecular weight       
430.62 
Structural formula  
    
Description 
Pale yellowish waxy solid 
                        Slightly odour 
                        Bland taste 
Physical property 
                                         Density-0.98 ˜  1.031 
                                        Melting point- 57
0
C HLB value-4.7 
       Flash point- > 110
0
C 
Category 
                                        Emulsifying agent, Nonionic surfactant, Solubilizing agent, 
Wetting agent and dispersing agent. 
Applications 
                                      It is used for cosmetic product, food products, and pharmaceutical 
formulations. 
                                     It is mainly used as an emulsifing agent in the preparation of creams, 
ointment and emulsion.  
Stability and Storage Condition 
                                    Gradual soap formation occurs with strong acid or bases, sorbitan 
esters are stable in weak acids or bases. Keep container tightly closed. Keep container in a 
cool, well ventilated area. Do not store above 24
0
C (72.2
0
F). 
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Solubility 
                                   Insoluble in cold water, soluble in ethanol, isopropanol, mineral oil, and 
vegetable oil. Insoluble in propylene glycol. 
Method of manufacture 
                                   Sorbitol is dehydrated to form hexitan(1,4- sorbitan), which is then 
esterified with the desired fatty acid. 
Handling Precaution 
1. Keep away from heat and sources of ignition. 
2. Avoid contact with eyes. 
3. Wear suitable protective clothing, in case of insufficient 
ventilation. 
4. Wear suitable respiratory equipment. (Handbook of pharmaceutical 
excipients. Edited by Raymond C Rowe,Paul J Sheskey) 
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                                                  CHOLESTEROL PROFILE 
Synonym  
Cholesterin 
Chemical name 
Cholest 5-en3β-ol 
Molecular formula 
C27H46O  
Molecular weight 
386.67 
Structural formula 
    
Description   
White or faintly yellow colour, almost odourless, pearly leaftlets, 
Needles, powder granules. 
Insoluble in water, soluble in vegetable oil. 
Physical property 
Boiling point : 360
0
C   
                        Melting point: 147
0
C-150
0
C  
                        Density :1.052g/cm
2 
                        Dielectric constant: 5.41. 
Category 
Emollient, emulsifying agent. 
Application 
                        It is mainly used in cosmetic and pharmaceutical formulations. 
                        It is used in the ointment preparation for emollient activity. 
                       Cholesterol additionally has a physiological role. 
 
 
Department of Pharmaceutics                                                                Cholesterol Profile                                                                                 
 
 
Nandha college of Pharmacy Page 47 
 
Stability and storage 
  Cholesterol is stable and should be stored in a well closed container, protected 
from light. 
Safety 
1. Cholesterol is generally regarded as an essentially non toxic and non 
irritant material at the level employed as an excipient. 
2. Cholesterol is often derived from animal sources and must be done so in 
accordance with the regulation for human consumption. 
HANDLING PRECAUTION 
1) May be harmful following inhalation or ingestion of large quantities,or over 
prolonged period of time, due to the possible involvement of cholesterol in 
atherosclerosis and gallstone. 
2) It may also causes irritation to eyes. 
3) Observe normal precautions appropriate to the circumstances and quantity of material 
handle. 
4) Rubber or plastic gloves, eye protection and a respirator are recommended. 
(Handbook of pharmaceutical excipients. Edited by Raymond C Rowe,Paul J Sheskey) 
 
 
 
Department of Pharmaceutics                                                                   Polymer Profile 
 
Nandha College of pharmacy, Erode 52. Page 48 
 
 
POLYMER PROFILE 
ETHYL CELLULOSE 
Synonym: Aquacoat ECD, Aqualon 
Chemical name: Cellulose ethyl ether  
Molecular formula: C12H23O6 
 Structural formula 
    
Description 
              It is tasteless. 
               Free flowing  
               White to light tan colour powder. 
               Freely soluble in chloroform, ethanol, ethyl aceate. 
               Practically soluble in glycerin, propylene  glycol. 
Physical property 
               Density: 0.4gm/cm
3 
              Glass transition temperature: 129-133
0
C 
   Refractive index:    1.14 
 
Category 
              Coating agent, flouring fixative, tablet binder, tablet filler, viscosity increasing 
agent. 
Application 
               It is used as a hydrophobic coating agent for tablet and capsules. 
               It is used to increase stability of formulations. 
               High viscosity ethyl cellulose are  used in drug encapsulation. 
            In topical formulations it is used as a thickening agent. (Handbook of 
pharmaceutical excipients. Edited by Raymond C Rowe,Paul J Sheskey) 
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AIM AND OBJECTIVE 
AIM 
  The present aim of the study was to develop a Proniosomal gel in transdermal 
patches system for Glipizide for the Treatment of Diabetics mellitus that is capable of 
efficiently delivering entrapped drug over an extended period of time.   
OBJECTIVE 
                         Glipizide is a second generation of sulfonylurea, it can accurately lowered the 
blood glucose level in humans by stimulating the release of insulin from the pancrease and is 
typically prescribed to treat type ll diabetics (non insulin dependent diabetic mellitus). The 
half life of glipizide is (3.4 ± 0.7 hours) necessitate it be administered in 2 or 3 doses of 2.5 to 
10mg per day.(www.pfizer.com) Thus the development of controlled- released dosage forms 
would clearly be advantageous. 
                         Proniosomal gels are semisolid liquid crystal products of nonionic surfactants 
easily prepared by dissolving the surfactant in a minimal amount of an acceptable solvent and 
the least amount of aqueous phase. Proniosomal gel offers a great potential to reduce the side 
effects of drugs and increased therapeutic effectiveness. (KiranYadav et al., 2010). 
                         The objective of the present study was to prepare proniosomal gel converted 
to transdermal patches in order to sustained release, increase the absorption rate, improve the 
drug efficiency, decrease the dose requirement, maintaining the concentration of the drug in 
the blood and decrease the renal excretion and maintaining the fluctuation of the dosage 
forms.    
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PLAN OF WORK 
 Review of Literature 
 Selection of drug and exicipients 
 Preformulation Studies 
 Confirmation of Drug 
 Determination of Drug Solubility 
 Color, Odor, Taste and Appearance  
 Determination of Melting Point 
 Determination of drug interaction by FT-IR 
 Determination of DSC 
 Formulation and Preparation methods 
                 Preparation of Proniosomal gel 
(Phase Coacervation separation Techniques) 
                Preparation of transdermal patches 
                        (Reservoir type transdermal patches) 
 Characterization of Proniosomal gel 
 PH Determination 
 Viscosity Determination 
 Entrapment efficiency 
 Drug Content 
 Vesicle size analysis 
 
 Evaluation of transdermal patches 
 In-vitro drug Release Study 
 In-vitro Skin Permeation study 
 Drug Release Kinetic Data Analysis 
 In-vivo Drug Release Study 
 Skin Irritation Study 
 Stability Study 
Result and Discussion 
Summary and Conclusion  
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MATERIALS AND INSTRUMENTS  
Materials Used  
The following materials were used for the preparation of proniosomal gel 
transdermal patches and their evaluation in their best quality available. 
 
Table no 1.  
Materials used for the research work  
S.No. Name Grade Company Name 
1. Glipizide Parma Wanbury  Limited, India 
2. Cholesterol   L.R  Loba Chem Pvt. Ltd., Mumbai   
3. Span 60 L.R Loba Chem. Pvt. Ltd., Mumbai   
4. Lecithin L.R  Loba Chem. Pvt. Ltd., Mumbai   
5. Isopropyl alcohol L.R  S.D.FineChem Ltd., Mumbai 
6. Glycerol L.R Loba Chem Pvt. Ltd., Mumbai 
7. Chloroform L.R  Loba Chem Pvt. Ltd., Mumbai 
8. Ethyl cellulose L.R Hi Media Laboratories Ltd, 
Mumbai. 
9. Poly ethylene glycol 400 L.R Loba Chem Pvt. Ltd., Mumbai 
10. Alloxan L.R Sigma chemicals, Bangalore 
11. Potassium di-hydrogen 
phosphate 
L.R  S.D.FineChem Ltd., Mumbai 
12. Sodium hydroxide L.R S.D. Fine Chem Ltd., Mumbai 
13. Distilled water L.R  Leo Scientific, Erode 
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Table no 2.  
Instruments Used For the Research Work 
S.No. Name Company Name 
1. Franz diffusion cell  Natural Scientific, Erode. 
2. Magnetic stirrer  Remi industries, Mumbai 
3. Electronic digital balance Schimadzu, Japan. 
4. Cooling centrifuge Remi industries, Mumbai 
5. US 800 Double beam  UV/VIS 
Spectrophotometer. 
Shimadzu, Mumbai 
6. Glucometer  Contour TS, Bayer poly 
chem. Limited, Thane 
7. FT-IR- 8400 Shimadzu, Mumbai. 
8. Sonicator Growell Instruments, 
Bangalore. 
9. Desicator Natural Scientific, Erode. 
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    EXPERIMENTAL WORK 
 
Preformulation studies 
  Preformulation testing was an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. The useful of 
Preformulation parameters maximizes the changes in formulation an acceptable, safe, 
efficacious and stable product and at same time provides the basis for optimization of the 
drug quality.  
Confirmation of Drug 
  Conformation of Drug was carried out by using UV spectroscopy. 2mg of 
drug dissolved in methanol and diluted with the same solvent. When UV spectrum of 
gilipizide solution in methanol was scanned at 200-400 nm, maxium was observed. 
Determination of Drug solubility 
  The solubility of glipizide was determined in water, dimethyl formamide, and 
0.1N NaOH was assayed. Excess of drug was added to known volume of the solvent system, 
vortex mixed for 2 minutes and then equilibrated at 37±0.5
o
C in more than 24 hrs. The 
contents were filtered and analyzed by uv visible spectrometer.  
Color, odor, taste and appearance 
  The drug sample was evaluated for its color and odor and results have been 
noted down.  
Melting point determination 
  Melting point of the drug sample was determined by capillary method using 
melting point apparatus. Taking a small amount of drug in a capillary tube closed at one end. 
The capillary tube was placed in the electrically operating melting point apparatus and 
temperature at which the drug melt was recorded.  The observed melting point was noted 
down. 
Drug interaction studies 
 FTIR 
                     The FTIR study has been carried out check the purity of drug. The FT-IR 
spectrum of pure drug and span 60, cholesterol and physical mixture of drug were analyzed 
for compatibility study. The samples were taken separately for FT-IR analysis. A milligram 
or less of the finely ground sample is intimately mixed with about 100 mg of dried potassium 
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bromide powder. Mixing can be carried out with a mortar and pestle; a small ball mill is more 
satisfactory, however. The mixture is then pressed in a special die at 10,000 to 15,000 pounds 
per square inch to yield a transparent disk. Best results are obtained if the disk is formed in a 
vacuum to eliminateoccluded air. The disk is then held in the instrument beam for 
spectroscopic examination.  
Differential Scanning Calorimetry 
  DSC pattern of glipizide, cholesterol and formulation complex were different f 
which give clear evidence that there is formation of the complexes with cholesterol were 
recorded using Shimadu D thermal analyzer (Japan). Samples were conserved in aluminium 
pan, the lid was pierced and the DSC thermogram was recorded at heating rate of 20
o
C/min 
from 60 to 240
o
C using nitrogen atmosphere. (Hanwate RM et al., 2011) 
Preparation of standard graph
 
   Standard curve of glipizide was prepared in phosphate buffer p
H
 7.4  
Procedure 
Accurately weighed (10mg) of glipizide was dissolved in 20ml of phospate buffer 7.4  
taken in 100ml calibrated volumetric flask and volume was made up to the mark using given 
buffer. 
From the stock solution, 0.5 ml of solution was withdrawn and diluted up to 10ml in 
volumetric flask this gives 5µg/ml. Similarly 10,15,20,25,30,35,40µg/ml were prepared by 
withdrawing 1,1.5,2,2.5,3,3.5,4,4.5ml respectively. Absorbance of eachsolution was 
measured at276nm. (Avinashsingh et al.,2011) 
Preparation of proniosomal gel 
Proniosomal gel was prepared by phase coacervationmethod. The weighed amount of 
surfactant (span 60), lipid (cholesterol), protein(egg lecithin) and drug were taken in a clean 
dry wide mouth glass container. The isopropyl alcohol was used as a solvent, it was added to 
2.5ml of above mixture and warm it. After warming all the ingredients were mixed well with 
a glass rod, the open end of the glass bottle was covered with the lid to prevent the loss of 
solvent. The temperature should be maintained at 60-70
o
C for (5 min) until the surfactant 
mixture dissolved completely. After dissolving the mixture, aqueous phase 1.6ml of 0.1% 
glycerol was added and warmed it till a clear solution was formed this was converted into 
proniosomal gel on cooling. The proniosomal gel was preserved in air tight container and 
stored in a dark place.(Ankurguptha et al.,2007, Chandra.A et al., 2008, IntakhabAlam et al., 
2010.). 
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               Figure no: 9Method of Preparation of Proniosomal Gel 
 
Table No: 1 Formulation of Different Proniosomal Gels 
Preparation of rate controlling membrane 
                                 Rate controlling membrane was prepared by solvent evaporation method.   
0.5 mg of ethyl cellulose polymer weighed anddissolved in 10ml of chloroform with Poly 
ethylene glycol asplasticizers. Then the solution is poured on the horizontal surface of 
Petridis and left for evaporation of solvent in order to obtain a thin film. (GeetaArrarwal et 
al., 2009). 
S.NO FORMULATION DRUG  
(mg) 
SPAN 60     
(mg) 
CHOLESTROL
(mg) 
LECITHIN 
(mg) 
1 F1 10 180 10 200 
2 F2 10 180 20 190 
3 F3 10 180 40 180 
4 F4 10 200 50 140 
5 F5 10 200 60 130 
6 F6 10 200 70 120 
7 F7 10 220 90 80 
8 F8 10 220 100 70  
9 F9 10 220 110 60 
10 F10 10 240 120 30  
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Preparation of drug reservoir and of transdermal patch 
                     The prepared proniosomal gels were fabricate by encapsuling within a shallow 
compartment of drug impermeable backing membrane(laminatedaluminum foil). A micro 
porous tape of larger area was stuck onto the impermeable backing membrane to bring the 
transdermal patch in close contact with the skin. The device was closed by a release linear on 
the open side. (Chandra Amrish et al., 2009) 
    
                     Figure No: 10 Fabrication design of reservoir type transdermal drug 
                                               Delivery of glipizide 
Evaluation 
P
H
 Determination 
  The P
H
 of each proniosomal gel was determined using P
H
 meter. The 
Electrode first calibrated with P
H
 4.0 and P
H
 7.0 solution, then reading were recorded on P
H
 
meter. (HemanthN.Patil et al., 2012) 
Viscosity Determination 
  The Viscosity of each Proniosomal gel was determined by using Brookfield 
viscometer with Spindle no: 64 at 20 rpm. (HemanthN.Patil et al., 2012) 
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Scanning electron microscopy 
  Particle size of Proniosomal gel is very important characteristic. The 
surface morphology (round, smoothness, and formation of aggregates) and the size analysis 
was performed by Scanning electron microscopy. Small amount of Proniosomal gel samples 
were placed on a stud and platinum was coated on them by Auto sputter fine coater. JFC 
1600, JEOL, Japan. Then the platinum coated samples were analyzed in a cold field emission 
scanning electron microscope, JEOL, JSM-6701F Japan and photographed. 
 
Entrapment efficiency 
  The 0.2 mg of proniosomal gel was taken with 10ml of phosphate buffer. The 
above mixture was sonicated in a sonicator bath. After that solution placed in centrifuge for 
centrifugation at 20,000 rpm at 20
o
C for 30 minute. The supernatant was collected and 
diluted with phosphate buffer. (Sandeep Gupta et al., 2009) The resulting solution was 
assayed by UV spectroscopy at 276nm. The percentage of encapsulation was calculated by 
following equation: 
Total drug concentration – concentration of free Drug 
%EE=            -------------------------------------------------------------------------------    X 100 
                                                          Total drug concentration 
Drug Content 
  The drug content was determined by 0.2gm proniosomal gel sample was 
withdrawn from container and dissolved in 10ml ethanol. Then the absorbance was measured 
by UV spectrometer against blank at 276 nm and the drug content was calculated. 
(HemanthN.Patil et al., 2012) 
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                               Fig No: 13 In-vitro skin Permeation study 
 
In-vitro Drug Release Study 
  In-vitro drug release studies were performed on a Franz diffusion cell with an 
effective diffusional area of 3.12 cm
2
. The cellophone membrane was mounted between the 
donor compartment and receptor compartment. The proniosomal gel converted into 
transdermal patch to be placed on one side of the cellophone membrane. The receptor 
compartment containing medium was phosphate buffer P
H
 7.4. The receptor compartment 
was surrounded by water jacket to maintain the temperature at 37±1
o
C. Heat was provided 
using a thermostatic hot plate with a magnetic stirrer. The receptor fluid was stirred by a 
Teflon coated magnetic bead fitted to a magnetic stirrer. At each sampling interval, 
sampleswere withdrawn and replaced equal volume of phosphate buffer. The samples were 
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filtered through a 0.2 µm filter membrane, absorbance of sample was measured UV-Visible 
spectrophotometer at 276nm against blank. The % of drug Release was plotted against 
time.(Kiranyadev et al., 2010). 
 
In-vitro skin Permeation Study 
  In-vitro skin permeation studies were performed on a Franz diffusion cell with 
an effective diffusional area of 3.465 cm
2
, properly thawed porcine skin was mounted 
between the compartments of the franz diffusion cell with the stratum corneum side facing 
the donor compartment and dermal side facing the receptor compartment. The patch to be 
tested was placed on the skin i.e in donor compartment. Phosphate buffer solution of P
H
7.4 
was used as receptor phase and the entire assembly was kept on a magnetic stirrer with 
continuous stirring of the solution in the receive compartment. Samples were withdrawn at 
regular periods through the sampling port and replaced by an equal volume of fresh buffer 
solution maintained at 37
o
C. The samples were filtered through a 0.2 µm filter membrane, 
absorbance of sample was measured UV-Visible spectrophotometer at 276nm against blank. 
The amount of drug permeated was plotted against time. (Shankar S.J et al.,2011, Shankar V 
et al., 2010) 
Drug Release Kinetic Data Analysis 
  The release data obtained from various formulations were studied further for 
their fitness of data in different the kinetics models like zero, first, Higuchi, Peppas. 
       In order to understand the kinetics and mechanism of drug release, the 
result of in-vitro drug release study of proniosomal gel were fitted with various kinetic 
equation like zero order as cumulative % release vs time, Higuchi model as log cumulative % 
drug release vs square root of time.r
2
 and k values were calculated for the linear curve 
obtained by regression analysis from the plots. 
  Zero order kinetics  Drug dissolution from pharmaceutics dosage forms that 
do not disaggrated andrelease the drug slowly, assuming the area does not change and no 
equilibrium conditions are obtained can be represents by the following equation: 
                                At=A0-k0t 
  Where, At= amount of drug dissolved in time t. A0 is the initial drug 
concentration.K0 is zero order rate constant (hr-1) when the data is plotted as cumulative 
percent drug release versus time, if plot is linear then the data obeys zero-order equal to K0. 
K0 zero order in units of conc/time and t is time in hours. 
First order Kinetics: 
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                       Predicted by equation; 
                                         Log C = log C0-Kt/2.30 
  Where, C is the amount of drug remained at time t, C0 is initial amount of drug 
and K is the first order rate constant (hr-1). When the data is plotted as log cumulative 
percent drug remaining vs time yields a straight line indicated that the release follow first 
order kinetics. The constant k can be obtained by multiplying 2.303 with the slope values. 
Higuchi model: 
                        Higuchi developed several theoretical models to study the release of water 
soluble and low soluble drug incorporated in semi solid or solid matrixes.  
                       Mathematical expression were obtained for drug particles dispersed in a 
uniform matrix behaving as the diffusion media and equation is 
Qt = KH.t1/2 
                        Where, Qt = amount of drug release in time t, KH = Higuchi constant. 
Krosmeyer and Peppas release model: 
                         To understand the release mechanism in-vitro data was analyzed by Peppas 
model. As log cumulative drug release vslog time and exponent n was calculated through the 
slope of the straight line. 
       Mt/Mα=btn 
                          Where, Mt is amount of drug release at time t, M is the overall amount of the 
drug, b, is constant and n is release exponent indicative of the drug release mechanism. 
(Shamsheer Ahmad et al., 2011, Chitta Suresh kumar et al., 2010). 
In-vivodrug release study 
  Animal approval  
 The study was conducted after obtaining the approval from Institutional animal ethics 
committee (IAEC), and the experimental procedures were in accordance to the guidelines of 
IAEC (688/02/c/CPCSEA). 
 
Selection of Animals  
  The mice weighing around 25-30gm was selected for the experiment. The 
animals were checked for the free of any disease, only the healthy rodent is accepted for the 
experiments. The male rodents are preferred so that there occur no interference between the 
experiments because of the pregnancy. The rodents were collected from the animal house of 
NandhaCollege of pharmacy and research institute, Erode 52. 
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Maintenance of animals 
 The selected male swiss albino mice were brought to the laboratory two days before the 
commencement of the experiment and provided with standard laboratory rodent chow diet 
obtained from (Pranav Agro Industries Ltd, Bangalore) and free access of water, 12 hrs 
day/dark cycle and room temperature is maintained 27
o
C. The night before the 
commencement of the experiment food is withdrawn but free access of water was provided. 
Induction of diabetics
 
  Adult male swiss albino mice were fasted for 24 hours with water and the 
initial blood sugar levels were checked. The animals were made diabetic by single 
intraperitoneal injection ofalloxan 200mg/kg of body weight and the blood glucose level  was 
raised this condition was observed at the end of 48 hours after alloxan 
injection.(ZhengweiZhoet al 2009.,) 
Groupingsof animals 
  Group I               =Control  
  Group II              =      Diabetic control  
  Group III             =Alloxan + Drug patch 
  Group IV             =Alloxan + Standard drug 
                        The drugs were dissolved in normal saline and it was administered orally via a 
standard gastric cannula. Anti-hyperglycemic activity in diabetic mice was assessed by fall in 
fasting blood glucose level (S.K.Guptha et al., 2009) Blood samples were collected from the 
tip on 0
th
, 1
st
, 2
nd
, 3
rd
upto 24 hrs.(V.Vats et al., 2002). By without scarifying the animal, from 
the tail vein by snipping off the tip of the tail and blood glucose was checked by glucometer.    
  For evaluating the hypoglycemic activity of glipizide loaded transdermal patches in 
mice. The hair on the posteriors abdomen of the mice was removed with an electric hair clipper. On 
the before three days were treated with standard drug and group  treated with test patches on the fasted 
mice skin whose hair previously removed. Blood samples were collected from the tip on 0
th
,  2
nd
, 
4
th
, 6
th
, 8
th
,10
th
, 16
th
up to 24 hrs. By without scarifying the animal, from the tail vein by 
snipping off the tip of the tail and blood glucose was checked by glucometer. (Manoj K 
mishra et al., 2009) 
Skin irritation Study 
The mice were divided into 3 groups (n=3). On the previous day of the experiment, the hair 
on the backside area of mice was removed. The animals of group I was served as normal, 
without any treatment. One group of animals (Group II) was applied with Test patch. A 0.8% 
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v/v aqueous solution of formalin was applied as a standard irritant (Group III). The animals 
were applied with new patch/formalin solution each day upto 7 days and finally the 
application sites were graded according to a visual scoring scale, always by the same 
investigator. The erythema scale was as follows: 0, none; 1, slight; 2, well defined; 3, 
moderate; and 4, scar formation. The edema scale was: 0, none; 1, slight; 2, well defined; 3, 
moderate; and 4, severe can be done by after visual evaluation of skin irritation. 
(SrinivasMutalik et al.,2005) 
Stability analysis 
  The ability of vesicles to retain the drug was assessed by keeping the 
proniosomal gel at three different temperature conditions, the conditions are refrigeration 
Temperature (4-8
o
C), Room temperature (25±2
o
C) and oven (45±2
o
C). Throughout the study, 
proniosomal formulations were stored in aluminum foil-sealed glass vials. The samples were 
withdrawn at different time interval over a period of two months and drug leakage from the 
formulations was analyzed for drug content. (HemanthN.Patil et al., 2012, Shankar et al., 
2010,Ankurguptha et al., 2007) 
 
Department of Pharmaceutics                                                              Result and Discussion 
 
Nandha College of Pharmacy,Erode 52. Page 63 
 
RESULTS AND DISSCUSION 
 
PREFORMULATION STUDY 
Preformulation testing is an investigation of Physical and Chemical Properties of a Drug 
Substance alone and when combined with excipients. It is first step in the lucidprogress. The 
overall objective of Preformulation testing is to make information useful to the formulator in 
developing stable and bioavailability dosage forms clearly, the type of information needed 
will be depends on the dosage form to be developed. The use of preformulation parameters 
maximizes thechanges in formulating an acceptable, safe, efficacious and stable product and 
at same time provides the foundation for optimization of the drug product quality. 
Confirmation of drug 
Glipizide in methanol solution was scanned at 200nm to 400nm, Maxima observed at 276 nm 
in methanol as showned in Spectra No:1 . This is confirmed with reported UV spectrum 
ofGlipizide. 
 
 
Spectra No: 1 UV- Visible Spectrum of Glipizide 
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Color, Odor, Taste and Appearance 
 
 
 
s 
 
 
Table No: 2 Results of identification tests of drug 
 
Determination of Solubility 
The solubility of glipizide was determined and found to be freely soluble in Dimethyl 
formamide and slightly soluble in 0.1N NaOH, poorly soluble in water. 
 
Melting point determination of Glipizide 
The melting Point of Pure drug of glipizide was determined by capillary method. The melting 
point drug was found to be 208
0
C. The melting point compared with standards that was found 
to be within a standard limits. 
Reported melting point Observed melting point 
208-209
0
C 209
0
C 
Table No: 3Melting point of Pure Drug 
 
Drug – Excipients Compatibility Study 
FT-IR spectra of glipizide, and physical mixture of drug were recorded to check the 
interaction between drug and physical mixture. The peak obtained due to pure glipizide at  
2941.5cm
-1
 (C-H alkane), 3324.42cm
-1
 (O-H Phenolic),1159.26 cm-
1
 (C-O Ether), 
1689.70cm
-1
 (C=O Ketone Stretching), 1033.88 cm
-1
 (S=O Sulfoxide Stretching), 1333.82 
cm
-1
 (C-N Amine Stretching), 686.68 cm
-1
 (C-H Bending), which is shown in Table No:4 . 
All these peaks have appear in spectra of Glipizide and Surfactant representing no chemical 
interaction between Drug and Surfactant without any markable change in the position and 
also not affected of transition temperature on indensity of peak appeared. It also confirmed 
that the stability of drug formulations. 
 
S.No Parameter Drug 
1. Color White 
2. Odor Odorless 
3. Taste Tasteless 
4. Appearance Crystalline 
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Transition Standard I.R range of 
Glipizide 
Observed value of Glipizide 
C-H (aromatic) 3050-3250 3251.13 
C=C (aromatic) 1450-1600 1527.67 
C-H (alkane) 2850-3000 2943.47 
C-N (amine) 1000-1350 1332.86 
C=O (ketone) 1650-1750 1689.70 
S=O (Sulphoxide) 950-1050 1033.88 
Table No:4Interpretation of FT-IR of Glipizide 
 
Transition Standard I.R range of 
Span 60 
Observed value of Span 6o 
O-H (alcoholic) 3200-3400 3258.84 
C-H (alkane) 2850-3000 2917.43 
C-O (ether) 1000-1300 1178.55 
Table No:5 Interpretation of FT-IR of Span 60 
 
Transition Standard I.R range of 
Cholesterol 
Observed value of 
Cholesterol 
O-H (alcoholic) 3200-3400 3427.62 
C-H (alkane) 2850-3000 2901.04 
C=C (alkene) 1600-1700 1671.37 
Table No: 6Interpretation of FT-IR of Cholesterol 
 
Transition Standard I.R range of 
Ethyl cellulose 
Observed value of Ethyl 
Cellulose 
C-O (ether) 1000-1300 1242.20 
C-H (alkane) 2850-2950 2888.24 
Table No: 7 Interpretation of FT-IR of Ethyl Cellulose 
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Transition Standard I.R 
range 
Observed value of 
Physical Mixture 
 
O-H (Phenolic) 3200-3400 3324.42 
C-H (alkane) 2859-3000 2941.54 
C-O (ether) 1000-1300 1159.26 
C=O (ketone) 1650-1750 1689.70 
S=O (sulphoxide) 950-1050 1033.88 
C-N (amine) 1000-1350 1333.82 
Table No: 8 Interpretation of FT-IR Physical Mixture 
 
 
                               Spectra No:2 IR Spectram of  Pure Drug of Glipizide 
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Spectra No: 3IR Spectrum of Span 60 
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Spectra No: 4IR Spectrum of Cholesterol 
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Spectra No: 5 IR Spectra of Ethyl Cellulose 
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Spectra No: 6 IR Spectra of Physical Mixture 
 
Differential Scanning Calorimetry 
The thermal behavior of Glipizide with cholesterol complex was studied using DSC in order 
to confirm the formation of semi solid complex. DSC thermograms of Glipizide complex are 
shown in spectra no:6. DSC thermograms of glipizide exhibited an endothermic peak at 
210.11
o
C corresponding to its melting point. DSC curves revealed that both cholesterol and 
Glipizide exhibited an endothermic peak with onset temperature of 148
o
C and 210.11
o
C 
respectively. These melting peaks indicated the crystalline nature of both components. 
Thethermograms of formulation complex are different from the pure drug, which gives clear 
evidence that there is formation of the complexes. 
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                                   Spectra No: 7 DSC Spectra of Glipizide pure drug 
 
Spectra No: 8 DSC Spectra of Cholesterol 
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                              Spectra No: 9 DSC Spectra of infusion Glipizide formulation 
Standard graph of Glipizide 
Standard curve of Glipizide in PBS P
H
 7.4 
Standard graph was prepared for concentration of 5µg/ml- 40µg/ml at 276 nm. The graph of 
absorbance vs concentration was plotted and data were subjected to linear regression analysis. 
The standard graph of drug in phosphate buffer show in table no: 9 
S.NO CONCENTRATION 
(µg/ml) 
ABSORBANCE 
1 5 0.113 
2 10 0.235 
3 15 0.376 
4 20 0.496 
5 25 0.628 
6 30 0.745 
7 35 0.871 
8 40 0.996 
Table No: 9 Standard Graph of Glipizide 
R
2
= 0.999
 
Slope=0.0252 
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Graph No: 1 Standard Graph of Glipizide 
Different Formulation categories of Proniosomal Gel: 
S.NO F. NO DRUG
(mg) 
SPAN60 
(mg) 
CHOLESTROL
(mg) 
LECITHIN 
(mg) 
OBSERVATION 
1 F1 10 180 10 200 Pale Yellowish Gel 
2 F2 10 180 20 190 Yellowish Gel 
3 F3 10 180 40 180 Yellowish Gel 
4 F4 10 200 50 140 Yellowish cream 
5 F5 10 200 60 130 Yellowish semi solid 
6 F6 10 200 70 120 Yellowish semi solid 
7 F7 10 220 90 80 Yellowish semi solid 
8 F8 10 220 100 70  Yellowish semi solid 
9 F9 10 220 110 60 Yellowish semi solid 
10 F10 10 240 120 30  Yellowish semi solid 
Table No: 10 Different State of Proniosomal Gel Preparations 
R² = 0.9997 
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   FigureNo:12ProniosomalgelFormulations
 
   Figure no: 12 Proniosomal gel used in transdermal patch  
 
 
 
P
H
 Determination 
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The ten different proniosomal gel P
H
 was determined by the P
H
 meter. 
S.NO Formulation Code P
H 
1. F1 6.90±0.14 
2. F2 6.98±0.32 
3. F3 6.89±0.57 
4. F4 6.91±0.41 
5. F5 6.93±0.58 
6. F6 6.87±0.36 
7. F7 6.90±0.78 
8. F8 7.07±0.27 
9. F9 7.11±0.58 
10 F10 7.18±0.63 
                             n=3 ±S.D*Table No: 11 P
H
 of Proniosomal Gel 
  Skin compatibility is the primary requirement for a good topical formulation, 
it was found that the pH of all the formulations were in the range of 6.87 to 7.18 that suits the 
skin pH, signifying skin compatibility. The results of pH determination are reported. The 
results were shown to the following table. No:11 
Viscosity Determination 
  The ten different Proniosomal gel Viscosity was determined by the Brookfield 
viscometer.Viscosityextent of all the formulations revealed optimum consistency and the 
results were shown to the following table no:12. 
S.No Formulation Code Viscosity 
1. F1 46127 
2. F2 45773 
3. F3 43672 
4. F4 42019 
5. F5 41371 
6. F6 38674 
7. F7 36096 
8. F8 35885 
9. F9 33098 
10. F10 32633 
n=3 ±S.D* 
Table No: 12 Viscosity Determinations 
Encapsulation Efficiency 
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The percentage Encapsulation Efficiency of six different Proniosomal formulations was 
found. The Encapsulation Efficiency is one of the main parameters in a plan of the 
Proniosomal formulations. The Encapsulation Efficiency relies on the stability of the vesicle 
which is greatly dependent on the type and amount of surfactant forming the bilayers, the 
amount of both cholesterol and lecithin. 
Effect on surfactant: 
The nonionic surfactant is the central building block of Proniosomal vesicle. The stability and 
Encapsulation Efficiency were highly affected by the essential properties of surfactant such 
as chemical structure and phase transition temperature. HLB value either increase or decrease 
it was indicate changes ofEncapsulationEfficiency. The chemical structure of span 60 which 
is length alkyl chains shown higher Encapsulation Efficiency. Span 60 having higher phase 
transition temperature were the largest partexpected in order to gel forming less leaky bi 
layers, so it produces higher EncapsulationEfficiency. 
Effect on Cholesterol: 
Cholesterol molecules are accommodate itself as vesicular observation in the molecule 
cavities formed monomers are assembled into bilayers to form Proniosomal membranes. This 
space filling action was in charge for higher inflexibility and less permeability of cholesterol 
containing membranes compared to cholesterol free membranes and improved percentage 
Encapsulation Efficiencyi.e very low level of cholesterol content to produce deceased 
EncapsulationEfficiency. In dissimilarity very high level cholesterol content decreased 
percentageEncapsulationEfficiency F3,F4,F5,F6 respectively 86.75 ±0.288, 87.75± 
0.803,87.25 ± 0.629,86.75 ± 0.381. This could be due to the information that cholesterol 
beyond a certain level starts disrupting the regular bi layered structure leading to loss of drug 
entrapment. The higher entrapment may be explained by high cholesterol content.In 
F2cholesterol level was responsible for producing higher (92.75± 0.520%) encapsulation 
efficiency. 
Effect of lecithin: 
Incorporation of lecithin is larger amount to produce higher percentage Encapsulation 
Efficiency which is commonly used to system stability. 
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S.NO FORMULATION 
CODE 
ENCAPSULATION 
EFFICIENCY* (%) 
1. F1 88.5 ± 0.250 
2. F2 92.75 ± 0.520 
3. F3 86.75 ±  0.288 
4. F4 87.75 ± 0.803 
5. F5 87.25 ± 0.629 
6. F6 86.75 ± 0.381 
7. F7 84.50 ± 0.381 
8. F8 83.50 ± 0.629 
9. F9 82.00± 0.750 
10. F10 81.75 ± 0.500 
n=3 ±S.D* 
Table No: 13 Encapsulation Efficiency Proniosomal Gel 
 
 
Graph No: 3 Entrapment Efficiency of Proniosomal Gel 
 
Drug Content 
Uniformity in content of proniosomal gel (F1 to F10) were confirmed to assure 
Uniformity in dosage. The results were reported in following table no:14 
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S.NO Formulation 
Code 
Drug Content 
1. F1 87.50± 0.144% 
2. F2 90.00± 0.25% 
3. F3 80.0±0.866 % 
4. F4 82.5± 0.520% 
5. F5 85.0±0.866% 
6. F6 75.0± 0.381% 
7. F7 70.0±0.577% 
8. F8 72.50± 0.381% 
9. F9 65.0±1.526% 
10. F10 62.5±1.041% 
n=3± S.D* 
Table No: 14 Drug Content of Proniosomal Gels 
 
 
Scanning Electron Microscopy 
Shape and surface characteristic of proniosomal gel examined by scanning electron 
microscopy analysis as shown fig No:  .the vesicles are shown smaller in diameter, and 
produce smooth surface area. 
 
 
 
Fig No: 14 SEM image of F2In-Vitro studies 
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In-Vitro Drug Release of F1 
Time Log time 
Sq.rt of 
time 
Absorbance 
conc 
µg/ml 
conc 
mg/ml 
% 
release 
cum % 
release 
log cum % 
release 
0 0 0 0 0 0 0 0 0 
1 0 1.000 0.066 2.619 0.655 6.548 6.548 0.816 
2 0.301 1.414 0.132 5.238 1.309 13.095 13.095 1.117 
3 0.441 1.732 0.201 7.976 1.994 19.940 19.940 1.299 
4 0.602 2.000 0.266 10.556 2.639 26.389 26.389 1.421 
5 0.699 2.236 0.341 13.532 3.383 33.829 33.829 1.529 
6 0.778 2.449 0.415 16.468 4.117 41.171 41.171 1.615 
7 0.845 2.645 0.495 19.643 4.911 49.107 49.107 1.691 
8 0.903 2.828 0.527 20.913 5.228 52.281 52.282 1.718 
9 0.903 2.828 0.575 22.818 5.704 57.044 57.044 1.756 
10 0.954 3.000 0.646 25.635 6.409 64.087 64.087 1.807 
11 1.000 3.162 0.727 28.849 7.212 72.123 72.123 1.858 
12 1.071 3.316 0.814 32.302 8.075 80.754 80.754 1.907 
18 1.342 3.464 0.886 35.159 8.789 87.897 87.897 1.944 
22 1.380 4.242 0.995 39.484 9.871 98.710 98.71 1.994 
24 1.380 4.899 0.998 39.603 9.901 99.008 99.008 1.996 
 
              Table no: 15 Invitro Drug Release Study of F1 
In-Vitro Skin Permeation Study 
 
S. No 
 
Time 
 
Absorbance 
Conc 
µg/cm
2
 
1 0 0 0 
2 1 0.059 2.341 
3 2 0.137 5.437 
4 3 0.213 8.452 
5 4 0.279 11.071 
6 5 0.347 13.769 
7 6 0.425 16.865 
8 7 0.502 19.921 
9 8 0.579 22.976 
10 9 0.651 25.833 
11 10 0.736 29.206 
12 11 0.824 32.698 
13 12 0.881 34.960 
14 18 0.893 35.861 
15 22 0.986 39.127 
16 24 0.998 39.603 
                               Table No:16In-vitro Skin Permeation Study of F1 
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Graph No: 4 In-vitro Drug Release of F1 
            
    Graph No: 5 In-vitroskin Permeation Study of F1 
 
 
0
20
40
60
80
100
120
0 5 10 15 20 25 30
%
 C
u
m
 D
ru
g 
R
e
le
as
e
 
Time in Hours 
In-Vitro Drug Release 
0
5
10
15
20
25
30
35
40
45
0 5 10 15 20 25   
   
   
  A
m
o
u
n
t 
o
f 
d
ru
g 
p
e
rm
e
at
io
n
 
µ
g/
cm
2
 
Time in Hours 
    Skin Permeation Study 
Department of Pharmaceutics                                                              Result and Discussion 
 
Nandha College of Pharmacy,Erode 52. Page 81 
 
                     
 
Graph No: 6 Higuchi Model of F1 
                 
                               Graph No: 7Korsmeyer-PeppasModel of F1 
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Formulation: 2 
 
S.No 
 
Time 
 
Sq.rt of 
time 
 
Absorbance 
 
Conc 
µg/ml 
 
Conc 
mg/ml 
 
Cum % 
Release 
Log 
Cum % 
Release 
1 0 0.000 0.000 0.000 0.0000 0.000 0.000 
2 1 0.000 0.075 2.976 0.744 7.44 0.872 
3 2 0.301 0.153 6.071 1.518 15.178 1.181 
4 3 0.441 0.231 9.167 2.292 22.917 1.360 
5 4 0.602 0.316 12.539 3.135 31.349 1.496 
6 5 0.699 0.389 15.437 3.859 38.591 1.591 
7 6 0.778 0.475 18.849 4.712 47.123 1.673 
8 7 0.845 0.553 21.944 5.486 54.861 1.739 
9 8 0.903 0.624 24.762 6.190 61.905 1.792 
10 9 0.954 0.691 27.421 6.855 68.552 1.836 
11 10 1.000 0.757 30.039 7.509 75.099 1.876 
12 11 1.041 0.808 32.063 8.016 80.158 1.904 
13 12 1.071 0.846 33.571 8.393 83.929 1.963 
14 18 1.255 0.925 36.706 9.177 91.769 1.986 
15 22 1.342 0.975 38.690 9.673 96.726 1.994 
16 24 1.380 0.986 39.125 9.781 98.710 1.990 
Table No: 17In-Vitro drug Release of F2 
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In-Vitro Skin Permeation 
 
S.No Time 
 
Absorbance 
Conc 
µg/cm
2
 
1 0 0 0 
2 1 0.071 2.817 
3 2 0.148 5.873 
4 3 0.227 9.008 
5 4 0.303 12.024 
6 5 0.384 15.238 
7 6 0.471 18.690 
8 7 0.547 21.706 
9 8 0.62 24.603 
10 9 0.686 27.222 
11 10 0.753 29.881 
12 11 0.8 31.746 
13 12 0.843 33.452 
14 18 0.921 36.548 
15 22 0.967 38.373 
16 24 0.991 39.325 
Table No:18In-Vitro Skin Permeation Study F2 
 
 
 
Graph No: 8In-Vitro Drug Release of F2 
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Graph No: 9 In-Vitro Skin Permeation Study of F2 
 
Graph No: 10 Higuchi Model of F2 
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Graph No: 11Korsmeyer-PeppasModel of F 
Formulation: 3 
 
S.No 
Time 
Log 
time 
Sq.rt of 
time 
Absorbance 
Conc 
µg/ml 
Conc 
mg/ml 
% Cum  
Drug 
Release 
Log % 
Cum 
Drug  
Release 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 0.000 1.000 0.061 2.421 0.605 6.052 0.782 
3 2 0.301 1.414 0.129 5.119 1.279 12.798 1.107 
4 3 0.044 1.732 0.189 7.500 1.875 18.750 1.273 
5 4 0.602 2.000 0.252 10.000 2.500 25.000 1.398 
6 5 0.699 2.236 0.327 12.976 3.244 32.44 1.511 
7 6 0.778 2.449 0.400 15.873 3.968 39.683 1.598 
8 7 0.845 2.646 0.476 18.889 4.722 47.222 1.674 
9 8 0.903 2.828 0.554 21.984 5.496 54.603 1.737 
10 9 0.954 3.000 0.633 25.119 6.279 62.198 1.794 
11 10 1.000 3.162 0.689 27.341 6.835 68.353 1.835 
12 11 1.041 3.317 0.751 29.802 7.450 74.504 1.872 
13 12 1.072 3.464 0.776 30.794 7.698 76.984 1.886 
14 18 1.255 4.242 0.86 34.127 8.532 85.317 1.931 
15 22 1.342 4.690 0.901 35.754 8.938 89.385 1.951 
16 24 1.380 4.899 0.927 36.786 9.196 91.964 1.964 
Table No: 19 In-vitro drug Release of F3 
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In-Vitro Skin Permeation Study 
S.No Time Absorbance Concµg/cm2 
1 0 0 0 
2 1 0.058 2.302 
3 2 0.123 4.881 
4 3 0.181 7.183 
5 4 0.247 9.802 
6 5 0.323 12.818 
7 6 0.396 15.714 
8 7 0.472 18.730 
9 8 0.548 21.746 
10 9 0.629 24.960 
11 10 0.687 27.262 
12 11 0.751 29.802 
13 12 0.769 30.516 
14 18 0.847 33.611 
15 22 0.893 35.437 
16 24 0.921 36.548 
Table No: 20 In-vitro Skin Permeation Study of F3 
 
 
Graph No: 12In-vitro drug release of F3 
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Graph No: 13 In-vitro Skin Permeation of F3 
 
Graph No: 14 Higuchi Model of F3 
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Graph No: 15Korsmeyer-PeppasModelof F3 
Formulation: 4 
 
 
S.No  
Time 
 
 
Log 
Time 
 
 
Sq.rt of 
Time 
 
Absorbance 
Conc 
µg/ml 
Conc 
mg/ml 
Cum % 
drug 
Release 
Log Cum 
% Drug 
Release 
1 0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 1 0.000 1.000 0.062 2.460 0.615 6.151 0.789 
3 2 0.301 1.414 0.129 5.119 1.279 12.798 1.107 
4 3 0.477 1.732 0.193 7.659 1.915 19.146 1.282 
5 4 0.602 2.000 0.255 10.119 2.529 25.298 1.403 
6 5 0.698 2.236 0.312 12.381 3.095 30.952 1.491 
7 6 0.778 2.449 0.361 14.325 3.581 35.813 1.554 
8 7 0.845 2.646 0.418 16.587 4.147 41.468 1.618 
9 8 0.903 2.828 0.473 18.769 4.692 46.925 1.671 
10 9 0.954 3.000 0.534 21.190 5.298 52.941 1.724 
11 10 1.000 3.162 0.595 23.611 5.903 59.0278 1.77 
12 11 1.041 3.317 0.648 25.714 6.429 64.286 1.808 
13 12 1.079 3.464 0.686 27.222 6.806 68.056 1.833 
14 18 1.255 4.242 0.787 31.230 7.808 78.0754 1.892 
15 22 1.342 4.69 0.841 33.373 8.343 83.433 1.921 
16 24 1.380 4.899 0.882 35.000 8.750 87.500 1.942 
Table No: 21In-vitro Drug Release of F4 
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In-Vitro Skin Permeation Study of F4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table No: 22In-Vitro Skin Permeation Study of F4 
 
 
Graph No: 16 In-vitro Drug Release of F4 
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S.No Time Absorbance Conc µg/cm
2
 
1 0 0 0 
2 1 0.067 2.659 
3 2 0.138 5.476 
4 3 0.196 7.778 
5 4 0.258 10.238 
6 5 0.319 12.659 
7 6 0.371 14.722 
8 7 0.425 16.865 
9 8 0.482 19.127 
10 9 0.541 21.468 
11 10 0.597 23.690 
12 11 0.653 25.913 
13 12 0.693 27.500 
14 18 0.789 31.309 
15 22 0.837 33.214 
16 24 0.867 34.405 
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Graph No: 17 In-vitro Skin Permeation Study of F4 
 
 
Graph No: 18 Higuchi Model of F4 
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Graph No: 19Korsmeyer-Peppas Model of F4 
 
Formulation:5 
 
S.NO 
Time 
Log 
time 
Sq.rt 
of time 
Absorbance 
Conc 
µg/ml 
Conc 
mg/ml 
% 
Cum 
Drug 
release 
Log Cum 
% Drug 
Release 
1 
0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2 
1 0.000 1.000 0.059 2.341 0.585 5.853 0.767 
3 
2 0.301 1.414 0.118 4.683 1.171 11.706 1.068 
4 
3 0.044 1.732 0.18 7.143 1.786 17.857 1.252 
5 
4 0.602 2.000 0.237 9.405 2.351 23.512 1.371 
6 
5 0.699 2.236 0.296 11.746 2.937 29.365 1.468 
7 
6 0.778 2.449 0.351 13.929 3.482 34.821 1.542 
8 
7 0.845 2.646 0.409 16.230 4.058 40.575 1.608 
9 
8 0.903 2.828 0.469 18.611 4.653 46.528 1.668 
10 
9 0.954 3.000 0.526 20.873 5.218 52.183 1.718 
11 
10 1.000 3.162 0.582 23.095 5.774 57.738 1.761 
12 
11 1.041 3.317 0.627 24.881 6.220 62.202 1.794 
13 
12 1.072 3.464 0.658 26.111 6.528 65.278 1.815 
14 
18 1.255 4.242 0.745 29.563 7.391 73.909 1.869 
15 
22 1.342 4.690 0.795 31.548 7.887 78.869 1.897 
16 
24 1.380 4.899 0.810 32.143 8.036 80.357 1.905 
 
Table No: 22In-vitro Drug Release of F5 
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In-Vitro Skin Permeation Study of F5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table No: 23 In-Vitro Skin Permeation Study of F5 
 
 
Graph No: 20 In-vitro Drug Release of F5 
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S.No 
 
Time 
 
Absorbance Conc µg/cm
2
 
1 0 0 0 
2 1 0.063 2.5 
3 2 0.121 4.802 
4 3 0.187 7.421 
5 4 0.245 9.722 
6 5 0.305 12.103 
7 6 0.359 14.246 
8 7 0.417 16.548 
9 8 0.473 18.769 
10 9 0.536 21.269 
11 10 0.589 23.373 
12 11 0.637 25.278 
13 12 0.669 26.548 
14 18 0.748 29.683 
15 22 0.8 31.746 
16 24 0.826 32.778 
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Graph No:21In-vitro Skin Permeation Study of F5 
 
 
Graph No:22 Higuchi Model of F5 
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Graph No:23Korsmeyer-Peppas Model  of F5 
 
Formulation: 6 
 
S.No 
Time 
Log 
time 
Sq.rt of 
time 
Absorbance 
Conc 
µg/ml 
Conc 
mg/ml 
% Cum 
Drug 
Release 
Log % 
Cum 
Drug 
Release 
 
1 
0 0.000 0.000 0.000 0.000 0.000 0.000 
0.000  
2 
1 0.000 1.000 0.051 2.024 0.506 5.059 
0.704  
3 
2 0.301 1.414 0.106 4.206 1.052 10.516 
1.022  
4 
3 0.044 1.732 0.148 5.873 1.468 14.682 
1.167  
5 
4 0.602 2.000 0.201 7.976 1.994 19.940 
1.299  
6 
5 0.699 2.236 0.254 10.079 2.519 25.198 
1.401  
7 
6 0.778 2.449 0.309 12.262 3.065 30.654 
1.486  
8 
7 0.845 2.645 0.362 14.365 3.591 35.913 
1.555  
9 
8 0.903 2.828 0.423 16.785 4.196 41.964 
1.623  
10 
9 0.954 3.000 0.474 18.809 4.702 47.024 
1.672  
11 
10 1.000 3.162 0.534 21.190 5.298 52.976 
1.724  
12 
11 1.041 3.316 0.589 23.373 5.843 58.433 
1.766  
13 
12 1.071 3.464 0.624 24.762 6.190 61.905 
1.792  
14 
18 1.255 4.242 0.686 27.222 6.806 68.056 
1.833  
15 22 1.342 4.69 0.725 28.769 7.192 71.925 1.857  
 
16 24 1.380 4.899 0.752 29.841 7.460 74.603 
 
1.873 
 
Table No: 23In-vitro Drug Release of F6 
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In-Vitro Skin Permeation Study of F6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                   Table no: 24In-vitro Skin Permeation Study of F6 
 
 
Graph No: 24In-vitro Drug Release of F6 
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S.No 
 
Time 
 
Absorbance 
Conc 
µg/cm
2
 
1 0 0 0 
2 1 0.051 2.024 
3 2 0.106 4.206 
4 3 0.148 5.873 
5 4 0.201 7.976 
6 5 0.254 10.079 
7 6 0.309 12.262 
8 7 0.362 14.365 
9 8 0.423 16.786 
10 9 0.474 18.809 
11 10 0.534 21.190 
12 11 0.589 23.373 
13 12 0.624 24.762 
14 18 0.686 27.222 
15 22 0.725 28.769 
16 24 0.752 29.841 
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Graph No: 25 In-Vitro Skin Permeation Study of F6 
 
 
 
Graph No: 26 Higuchi Model of F6 
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Graph No: 27Korsmeyer-PeppasModelof F6 
 
In-Vitro Drug Release [ F1-F6] 
 
 
Graph No: 28In-Vitro Drug Release of F1-F6 
  In-vitro percentage drug release studies were performed to the release of the 
drug from different sixproniosomal gel converted to transdermal patches formulations. Most 
of the formulations were found to have linear release and the formulations were found to 
provide approximately 90% (F2, F3) release within a period of 24 hours. The formulations 
which have higher concentration of cholesterol level were found to the sustained release but 
percentage  drug release was decreased. 
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In-vitro skin permeation studies were found to the six different proniosomal gel transdermal 
patches exhibits the greatest amount of drug permeation were followed 
39.325µg/cm
2
,36.548µg/cm
2
 (F2,F3) at the end of 24 hours. 
Comparative Study for Glipizide Matrix Patch and Formulation F2 
                   
        Graph No: 29 Comparative Studies of Matrix Patch    
  The formulation F2 was Show better percentage Cumilative drug release than 
compared to matrix patch of glipizide. 
Pharmacokinetics drug release 
 
Diffusion release exponent Overall solute diffusion 
mechanism 
0.5 Fickian Diffusion 
0.5<n< 1.0 Anomalous (Non-Fickian) 
Diffusion 
1.0 Case II transport 
n>1.0 Super Case II transport 
 
Table No: 25 Pharmacokinetics of Drug Release 
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F.No 
 
Zero Order  
 
Higuchi Order  
KROSMEYER AND 
PEPPAS RELEASE 
MODEL 
  R
2
 R
2
 n R
2
 
F1  0.948 0.968 0.980 0.973 
F2  0.948 0.982 0.992 0.991 
F3  0.979 0.974 0.984 0.983 
F4  0.939 0.976 0.979 0.978 
F5  0.940 0.978 0.987 0.965 
F6  0.941 0.971 0.981 0.966 
 
Table No: 26 Different Release order 
The zero order plots showed the zero order release characteristics of the formulation, which 
was confirm by the correlation value. The release profile of F1,F2,F3,F4,F5,F6 could be best 
explained by Higuchi Model, as plots showed high linearity, with correlation coefficient (R
2
) 
values 0.968,0.982,0.974,0.976,0.978,0.971respectively. From this result was diffusion 
mechanism was conformed. The diffusion mechanism of drug release was further confirmed 
by Korsmeyer-Peppas plots that showed fair linearity than compare to Higuchi diffusion(R
2
 
values between0.966 to 0.983).According to this correlation valueindicating the mechanism 
of drug release was diffusion. 
In-Vivo Drug Release Study 
The in-vivo Drug release was optimized formulation (F2) to produce sustained release and 
effectiveness than compare to standard drug. 
 
 
Fig No: 14 In-vivo Drug Release Study on Mice 
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Drug   
treatment 
Initial 
After 
Induction of 
Alloxan           
(0hrs) 
2 hrs 4 hrs 6 hrs 10 hrs 16 hrs 24 hrs 
Control Goup 
116.33±2.
33 
119.66±2.02 117.33±2.4 116.1±1.05 118.1±1.48 116.33±1.28 119.0±2.02 121.66±1.52 
Alloxan 
Induced 
Group 
109.33±1.
76 
219.8±1.88 223.66±1.1 225±2.47 227.0±1.18 229.5±1.72 234.66±1.84 238.33±1.37 
Test 
(Alloxan+ 
Test Patch) 
112±1.24 231.66±1.55 228.2±1.82 211.2±1.46 
 
194.2±1.89
* 
 
172.66±2.27*
* 
153.11±0.46 
 
132.33±2.42
** 
Standard 
Drug (oral 
administratio
n) 
111±1.24 227.33±2.36 207.9±1.14 
 
183.5±1.51
* 
 
137.5±1.51
** 
217.33±2.52 215±2.27 221.66±2.27 
Data represents mean ± SEM. (n=3); *p<0.05; **p<0.01 
Table No : 27 In-vivo Drug Release Study 
 
 
Graph No: 30In vivo Drug Release of F2 
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Skin Irritation Study 
    
 
 
 
 
 
Table No: 30 Skin Irritation Study 
 
  The standard irritant, formalin produced severe erythema and edema. Formalin 
produced high grade of irritation, indicated by `severe' inflammation and edema besides 
showing discontinuity in epidermis, thin epidermis, ulceration and hyperplasia. Then 
compare to formalin the test patch was produce less erythema and edema. 
 
 
 
Stability Analysis 
  Stability analysis carried out to the optimized formulation. The amount of drug 
retained. The result shown thepronisomal gel formulation was quite stable at refrigeration and 
room temperature as not leakage of drug was found at these temperatures. 
 
Table No: 28 Stability Study of F2 
 
 
Formulation  
Visual observation 
Erythema Edema 
Normal 0.00±0.00 0.00±0.00 
Test Patch 1.16±0.16 1.33±0.40 
Formalin (0.8% v/v) 3.64±0.33 3.48±0.22 
Weeks 0 2 4 6 8 
Refrigerator 
Tempt 
(4-8
o
C) 
100% 100% 99% 99% 98% 
Room Tempt 
(25±2
o
C) 
100% 99% 98% 95% 92% 
Oven Tempt 
(45±2
o
C) 
100% 91% 72% 56% 34% 
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Graph N0: 31 Stability Study of F2 
 
 
 
Fig No :15Sem Image of F2 after two months 
 
The percentage drug retained at evaluated temperature (45
o
C) it should have decreased due to 
the melting of the surfactant. From the results of vesicular size and shape was similar then 
compared to SEM of optimized formulation (F2) before 2 months Fig No: 14. Therefore the 
proniosomal gels were stored in room or refrigeration temperature. 
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SUMMARY AND CONCLUSION 
   In the present study, a variety of Proniosomal gels were prepared by phase 
coservation method with different ratio of surfactant, cholesterol and lecithin. 
   Drug polymer interactions were studied using FT-IR analysis. The result 
shows there was no change in the spectra of pure drug glipizide alone and physical mixture. 
The DSC study of drug and cholesterol and infusion drug complex showed that there was no 
major difference in DSC thermogram.  
   The morphology of prepared Proniosomal gel was observed under SEM. It 
was produce good spectral smooth surface area is substantiation by the photographs. The 
observed vesicles with small diameter to permeate through the skin as small vesicle tend to 
fuse readily.   
   Proniosomal gel was produce high entrapment efficiency by using the alcohol, 
from the results of entrapment efficiency to depend upon the cholesterol level. The amount of 
cholesterol level increase to produce higher entrapment efficiency. Incorporation of lecithin 
to produce act as a permeation enhancer. According to the evaluation parameter like nature of 
the formulations, Viscosity, entrapment efficiency and drug content to the following 
formulations F7,F8,F9,F10 cannot be applied to the transdermal patches. So it can be avoid for 
the further steps. 
   Remaining formulation F1,F2,F3,F4,F5,F6 can be taken for remaining studies. In 
this, in-vitro study showed the drug release was decreases by increase the amount of 
cholesterol content. The formulation F2 showed good of skin permeation (39.325 µg/cm
2
) and 
cum percentage of drug releases (98.710%) at end of 24 hours.  The in-vitro release applied 
various kinetic models. It was showed Zero order release which confirmed diffusion 
mechanism by the correlation value from proniosomal gel convert transdermal patches. 
Correlations value of Higuchi’s plot were in between 0.968 to 0.989 which revealed that the 
mechanism of drug release and further more  Korsmeyer-Peppas correlation values ranges 
from 0.965 to 0.991also confirmed the diffusion mechanism.   
   The In-vivo efficiency tests with compared standard drug (glipizide) to give 
oral administration and optimized formulation Proniosomal gel converted to transdermal 
patch formulation (F2) was performed swiss albino mice by measuring the hypoglycemic 
effect. Result showed that formulation F2 had good effectiveness then standard drug solution 
and also to produce extended hypoglycemic effect may be due to sustained release of 
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glipizide from Proniosomal gel  transdermal patch. In Skin irritation Study, test patches were 
produce less erythema, edema and negligible side effects. 
   Based on the entrapment efficiency, Release study, kinetic models and drug 
content formulation F2 was subjected for stability studies carried out various storage 
conditions. The percentage of drug content after a period of two months for 2-8
o
C, 25
o
C± 
0.5
o
C and 45
o
C were found to be 98%, 92% and 34% respectively. Observed that the result 
proniosomal gel transdermal patches were stable under refrigeration temperature and room 
conditions with least leakage. 
 
 This project was design to investigate the chance of manufacturing to Proniosomal gel 
transdermal patches. The result indicated the Proniosomal gels were very promising 
drug carriers. 
 The present formulation study on glipizide is an effort to prepare Proniosomal gel 
converted into the transdermal patches and to evaluate the performance. The content 
of nonionic surfactant and cholesterol is evaluated in this study.  
 The best formulation of Proniosomal gel was one which have high efficiency is found 
to be surfactant and cholesterol content dependent. The release rate is also depending 
upon surfactant and cholesterol content. 
 The FT-IR studies indicated no chemical interactions between drug, other exicipients 
and stability of drug during the method of preparations. 
 The formulation F2 which shows higher entrapment efficiency was 92.75%. In-vitro 
release study of F2 shows release 98.710% and drug permeation 39.325µg/cm
2
 at the 
end of 24 hrs which shows sufficient release of drug in phosphate buffer. The in-vitro 
release data applied to various kinetic models to predict the drug release kinetics. 
Values were obtained from Higuchi’s, Peppa’s plot verifies result to Diffusion 
mechanism and zero order kinetics. 
 By this facts study can be concluded the Proniosomal gel transdermal patches showed 
controlled drug release properties. The combination of cholesterol and surfactant 
ratios was to produce sustained release of over a long period of 24 hours for the 
management of diabetics.  
 This Proniosomal  transdermal patches as a device, penetrate to the skin barrier along 
to the skin moisture gradient. This Proniosomal gel is containing component that 
stabilize the lipid bi layer and thus important to comfortable vesicle.       
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 The Proniosomal gel could be an effective alternative vehicle for delivering the drug 
through transdermal route to avoid side effects, first pass metabolism, GI irritations, 
patient compliance associated with oral route. Proniosomal Gel transdermal patches 
were highly stable, more rate of Drug release and reducing the drug degradation then 
compared to other type of transdermal patches.  
 The method of preparation of Proniosomal gel transdermal patches is very simple, do 
not involved long procedure and using limited number of pharmaceutical exicipients. 
 In the commercial market very less number of transdermal patches are available. So 
may be our formulation proniosomal gel transdermal type patches are potential and 
ideally suitable for diabetic patients. 
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